[CAS NO. 205923-56-4] Cetuximab
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [205923-56-4]
Store
Catalog
HY-P9905
Brand
MCE
CAS
205923-56-4
DESCRIPTION [205923-56-4]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 145543.35 |
| Molecular Formula | - |
| SMILES | [Cetuximab] |
For research use only. We do not sell to patients.
15 Publications Citing Use of MCE
- [1]Cell Res. 2022 Oct 14.
- [2]Cell Res. 2020 Dec;30(12):1063-1077.
- [3]Mol Cancer. 2021 Jan 18;20(1):17.
- [4]Am J Respir Crit Care Med. 2022 Jul 11.
- [5]Nat Commun. 2022 Feb 1;13(1):594.
- [6]Genome Med. 2021 Apr 14;13(1):58.
- [7]J Cell Biol. 2021 Nov 1;220(11):e202107103.
- [8]Theranostics. 2020 Apr 6;10(11):5107-5119.
- [9]Oncogene. 2021 Mar 8.
- [10]Int J Mol Sci. 2022 Aug 6;23(15):8754.
- [11]J Cell Mol Med. 2020 Jul;24(13):7313-7330.
- [12]Sci Rep. 2022 Jul 7;12(1):11561.
- [13]Bioorgan Med Chem. 2022: 117114.
- [14]Visualizing and Quantifying Drug Distribution in Tissue V. 116240F (2021).
- [15]bioRxiv. 2020 Jun.
Summary
IC50 & Target
|
EGFR 0.147 nM (Kd, Fixed A431 cells) |
Soluble EGFR 0.201 nM (Kd) |
In Vitro
Cetuximab (C225) is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a K d of 0.201 nM for soluble EGFR by SPR. Cetuximab also exhibits a K d of 0.147 nM for EGFR in fixed A431 cells by ELISA [1] . Cetuximab (C225; 30 nM) time-dependently inhibits the proliferation of SCC-1, SCC-11B, SCC-38, and SCC-13Y cells after treatment for 8 d. Cetuximab (30 nM) causes G 0 /G 1 arrest, induces apoptosis, and reduces Rb, p27 KIP1 , Bcl-2, and Bax expression in SCC-13Y cells. Cetuximab (30 nM) also enhances radiosensitivity and increases radiation-induced apoptosis in SCC-13Y cells [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Cetuximab (1 mg/injection) has effect on the tumour volume but the effect is more pronounced on UT-SCC-14 xenografts. In UT-SCC-14 xenografts, Cetuximab treatment significantly reduces the expression of EGFR, pEGFR and Ki67. The MCT1 and GLUT1 expression is significantly decreased in the Cetuximab-treated groups of both cell lines but differences are more pronounced in UT-SCC-14 xenografts [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01802645 | Technische Universität Dresden |
Colorectal Cancer
|
March 2013 | Phase 2 |
| NCT00004227 | University of Alabama at Birmingham|National Cancer Institute (NCI) |
Head and Neck Cancer
|
April 1999 | Phase 3 |
| NCT00747097 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Merck Sharp & Dohme LLC |
Time to Progression
|
September 2008 | Phase 2 |
| NCT00319839 | University of California, Irvine |
Head and Neck Cancer
|
March 2006 | Phase 2 |
| NCT05217446 | Pfizer|Merck Sharp & Dohme LLC|Merck KGaA, Darmstadt, Germany|Eli Lilly and Company |
Metastatic Colorectal Cancer
|
July 11, 2022 | Phase 2 |
| NCT00541112 | UNICANCER |
Colorectal Cancer
|
October 29, 2007 | Phase 2 |
| NCT05358249 | Novartis Pharmaceuticals|Novartis |
KRAS G12C Mutant Solid Tumors|Carcinoma, Non-Small Cell Lung|Carcinoma, Non-Small-Cell Lung|Non-Small Cell Lung Cancer|Non-Small Cell Lung Carcinoma|Nonsmall Cell Lung Cancer|Colorectal Cancer|Colorectal Carcinoma|Colorectal Neoplasms|Colorectal Tumors|Neoplasms, Colorectal
|
October 24, 2022 | Phase 1|Phase 2 |
| NCT03258554 | National Cancer Institute (NCI)|Canadian Cancer Trials Group|NRG Oncology |
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Head and Neck Squamous Cell Carcinoma|Hypopharyngeal Squamous Cell Carcinoma|Laryngeal Squamous Cell Carcinoma|Oral Cavity Squamous Cell Carcinoma|Oropharyngeal Squamous Cell Carcinoma|Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Squamous Cell Carcinoma of Unknown Primary|Stage III Hypopharyngeal Carcinoma AJCC v8|Stage III Laryngeal Cancer AJCC v8|Stage III Lip and Oral Cavity Cancer AJCC v8|Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8|Stage IVA Hypopharyngeal Carcinoma AJCC v8|Stage IVA Laryngeal Cancer AJCC v8|Stage IVA Lip and Oral Cavity Cancer AJCC v8|Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8|Stage IVB Hypopharyngeal Carcinoma AJCC v8|Stage IVB Laryngeal Cancer AJCC v8|Stage IVB Lip and Oral Cavity Cancer AJCC v8|Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
|
December 12, 2017 | Phase 2|Phase 3 |
| NCT02624128 | National Cancer Institute, Naples |
Squamous Cell Carcinoma of the Head and Neck
|
February 23, 2015 | Phase 2 |
| NCT02296203 | Gruppo Oncologico del Nord-Ovest |
Metastatic Colorectal Cancer
|
October 2014 | Phase 2 |
| NCT00617734 | Eli Lilly and Company |
Head and Neck Cancer
|
March 2008 | Phase 2 |
| NCT04525326 | Fudan University |
Colorectal Cancer|Liver Metastases
|
October 1, 2020 | Phase 3 |
| NCT00725400 | American Scitech International|Eli Lilly and Company|Bristol-Myers Squibb |
Colorectal Carcinoma
|
February 2010 | Phase 2 |
| NCT00248287 | US Oncology Research|Bristol-Myers Squibb|Pfizer |
Metastatic Breast Cancer
|
July 28, 2005 | Phase 2 |
| NCT01884259 | Arbeitsgemeinschaft medikamentoese Tumortherapie |
Squamous Cell Carcinoma of the Hypopharynx Stage III|Squamous Cell Carcinoma of the Hypopharynx Stage IV|Squamous Cell Carcinoma of the Larynx Stage III|Squamous Cell Carcinoma of the Larynx Stage IV|Squamous Cell Carcinoma of the Oropharynx Stage III|Squamous Cell Carcinoma of the Oropharynx Stage IV|Squamous Cell Carcinoma of the Oral Cavity Stage III|Squamous Cell Carcinoma of the Oral Cavity Stage IV
|
May 2013 | Phase 2 |
| NCT01445405 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer
|
February 5, 2008 | Phase 1 |
| NCT04687631 | Fudan University |
Colorectal Cancer|Liver Metastases
|
January 14, 2021 | Phase 3 |
| NCT00857246 | NYU Langone Health|Bristol-Myers Squibb|Eli Lilly and Company |
Gastric Cancer|Stomach Cancer
|
July 2005 | Phase 2 |
| NCT01198535 | National Cancer Institute (NCI) |
Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer
|
September 2010 | Phase 1 |
| NCT01588431 | The University of Texas Health Science Center at San Antonio |
Carcinoma, Squamous Cell of Head and Neck
|
December 2011 | Phase 2 |
| NCT05239741 | Merck Sharp & Dohme LLC |
Colorectal Neoplasms
|
April 2, 2022 | Phase 3 |
| NCT01338558 | Hoffmann-La Roche |
Colorectal Cancer
|
June 2011 | Phase 3 |
| NCT02764593 | RTOG Foundation, Inc.|Bristol-Myers Squibb |
Head and Neck Squamous Cell Carcinoma (HNSCC)
|
June 2016 | Phase 1 |
| NCT02241187 | Memorial Sloan Kettering Cancer Center|Cold Spring Harbor Laboratory|Weizmann Institute of Science |
Pancreatic Cancer
|
September 12, 2014 | Not Applicable |
| NCT00538291 | City of Hope Medical Center|National Cancer Institute (NCI) |
Colorectal Cancer
|
August 2005 | Phase 2 |
| NCT00766142 | Institut Bergonié|Assistance Publique - Hôpitaux de Paris|Centre Alexis Vautrin, Nancy|Centre Leon Berard|Institut Cancerologie de l´Ouest|Hôpital Haut-Lévêque|Clinique Francheville, Périgueux |
Colorectal Cancer|Primary Peritoneal Cavity Cancer
|
May 1, 2007 | Phase 2 |
| NCT00004865 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)|Eli Lilly and Company |
Head and Neck Cancer
|
November 1999 | Phase 2 |
| NCT00908024 | Bristol-Myers Squibb |
Colorectal Cancer|Head and Neck Cancer|Neoplasm Metastasis
|
October 2009 | Phase 1|Phase 2 |
| NCT00162110 | Eli Lilly and Company |
Mucinous Gastrointestinal Adenocarcinoma
|
November 2004 | Phase 2 |
| NCT04375384 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Head and Neck Squamous Cell Carcinoma|Recurrent Head and Neck Squamous Cell Carcinoma|Metastatic Head-and-neck Squamous-cell Carcinoma
|
July 1, 2020 | Phase 2 |
| NCT04278092 | Medical University of Vienna |
Head and Neck Squamous Cell Carcinoma
|
February 10, 2020 | Phase 2 |
| NCT00130689 | Dana-Farber Cancer Institute|Bristol-Myers Squibb|Massachusetts General Hospital|Beth Israel Deaconess Medical Center |
Esophageal Cancer|Gastric Cancer|Neoplasm Metastasis
|
July 2005 | Phase 2 |
| NCT04672772 | Grupo Español de Tratamiento de Tumores de Cabeza y Cuello|Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany |
Squamous Cell Carcinoma of the Head and Neck
|
December 18, 2020 | |
| NCT02124148 | Eli Lilly and Company |
Neoplasm Metastasis|Colorectal Neoplasms|Breast Cancer
|
June 18, 2014 | Phase 1 |
| NCT04189055 | GCS IHFB Cognacq-Jay |
Cancer Colorectal
|
January 7, 2020 | Phase 2 |
| NCT00598975 | Nektar Therapeutics |
Tumor|Colorectal Cancer
|
February 2008 | Phase 2 |
| NCT02817113 | Orient Europharma Co., Ltd.|NanoCarrier Co., Ltd. |
Head and Neck Neoplasms
|
June 2016 | Phase 1 |
| NCT03365882 | Southwest Oncology Group|National Cancer Institute (NCI) |
Colon Adenocarcinoma|ERBB2 Gene Amplification|Rectal Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage III Colon Cancer AJCC v7|Stage III Rectal Cancer AJCC v7|Stage IIIA Colon Cancer AJCC v7|Stage IIIA Rectal Cancer AJCC v7|Stage IIIB Colon Cancer AJCC v7|Stage IIIB Rectal Cancer AJCC v7|Stage IIIC Colon Cancer AJCC v7|Stage IIIC Rectal Cancer AJCC v7|Stage IV Colon Cancer AJCC v7|Stage IV Rectal Cancer AJCC v7|Stage IVA Colon Cancer AJCC v7|Stage IVA Rectal Cancer AJCC v7|Stage IVB Colon Cancer AJCC v7|Stage IVB Rectal Cancer AJCC v7
|
October 9, 2017 | Phase 2 |
| NCT01090011 | Boehringer Ingelheim |
Carcinoma, Non-Small-Cell Lung
|
March 2010 | Phase 1 |
| NCT02124707 | UNC Lineberger Comprehensive Cancer Center |
Head and Neck Cancer|Squamous Cell Carcinoma of the Head and Neck
|
June 16, 2014 | Phase 2 |
| NCT00721513 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Head and Neck Cancer
|
September 2008 | Phase 2 |
| NCT01285037 | Eli Lilly and Company |
Cancer
|
September 9, 2009 | Phase 1 |
| NCT05002270 | Jacobio Pharmaceuticals Co., Ltd. |
Advanced Solid Tumor|NSCLC|CRC
|
September 3, 2021 | Phase 1|Phase 2 |
| NCT03691714 | Trisha Wise-Draper|AstraZeneca|University of Cincinnati |
Recurrent Head and Neck Cancer|Head and Neck Cancer|Head and Neck Neoplasms|Metastatic Cancer
|
October 23, 2018 | Phase 2 |
| NCT01051167 | Martin Schuler, Prof. Dr. med.|Universität Duisburg-Essen |
Metastatic Colorectal Cancer
|
February 2009 | Phase 2 |
| NCT00392470 | Centre Hospitalier Universitaire Vaudois|National Cancer Institute (NCI) |
Colorectal Cancer
|
August 2006 | Phase 1 |
| NCT02015650 | Medical University Innsbruck |
Head and Neck Neoplasms
|
April 2014 | Phase 4 |
| NCT00543504 | M.D. Anderson Cancer Center |
Advanced Cancer
|
October 10, 2007 | Phase 1 |
| NCT00290615 | Herbert Hurwitz|National Cancer Institute (NCI)|Duke University |
Colorectal Cancer
|
January 2006 | Phase 2 |
| NCT00288054 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lung Cancer
|
April 2006 | Phase 1 |
| NCT00867009 | Eli Lilly and Company |
Non-Small-Cell Lung Cancer
|
April 2009 | Phase 2 |
| NCT00492206 | University of Pittsburgh|Bristol-Myers Squibb |
Non Small Cell Lung Cancer (NSCLC)
|
June 2006 | Phase 2 |
| NCT03667482 | Memorial Sloan Kettering Cancer Center |
Head and Neck Squamous Cell Cancer|Recurrent Head and Neck Squamous Cell Cancer|Metastatic Head and Neck Squamous Cell Cancer
|
September 7, 2018 | Phase 1 |
| NCT05249426 | Boehringer Ingelheim |
Head and Neck Squamous Cell Carcinoma (HNSCC)
|
February 25, 2022 | Phase 1 |
| NCT00728663 | Swiss Group for Clinical Cancer Research |
Prostate Cancer
|
June 2008 | Phase 2 |
| NCT03494322 | University College, London|Merck KGaA, Darmstadt, Germany |
Head and Neck Cancer|Squamous Cell Carcinoma
|
July 20, 2018 | Phase 2 |
| NCT01878422 | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
Metastatic Colorectal Cancer
|
November 2007 | Phase 3 |
| NCT00479752 | Central European Cooperative Oncology Group |
Colorectal Cancer
|
January 2008 | Phase 2 |
| NCT01102231 | Intergroupe Francophone de Cancerologie Thoracique |
Stage III Non-small Cell Lung Cancer
|
March 2010 | Phase 2 |
| NCT00714649 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Merck Sharp & Dohme LLC|Merck Serono International SA |
Head and Neck Cancer
|
July 2008 | Phase 1|Phase 2 |
| NCT02717923 | Huazhong University of Science and Technology|The First Affiliated Hospital of Nanchang University|Hunan Cancer Hospital|Henan Cancer Hospital |
Colorectal Neoplasms
|
January 2014 | Phase 2 |
| NCT00055419 | Eli Lilly and Company|Bristol-Myers Squibb |
Colorectal Neoplasms
|
February 2003 | Phase 2 |
| NCT05041127 | M.D. Anderson Cancer Center |
Chordoma|Metastatic Chordoma|Unresectable Chordoma
|
May 27, 2022 | Phase 2 |
| NCT00940381 | M.D. Anderson Cancer Center |
Advanced Cancer
|
July 2009 | Phase 1 |
| NCT00154102 | Merck KGaA, Darmstadt, Germany |
Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer
|
May 2004 | Phase 3 |
| NCT00101192 | Gynecologic Oncology Group|National Cancer Institute (NCI)|Bristol-Myers Squibb|GOG Foundation |
Cervical Cancer
|
September 2004 | Phase 2 |
| NCT01564810 | Xu jianmin|Fudan University |
Colorectal Neoplasms|Neoplasm Metastasis|Liver Neoplasms
|
September 2006 | Phase 4 |
| NCT00870870 | Eli Lilly and Company |
Non-Small Cell Lung Cancer
|
March 2009 | Phase 2 |
| NCT00871169 | New Mexico Cancer Care Alliance |
Pancreatic Cancer
|
October 2008 | Phase 2 |
| NCT00089297 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Head and Neck Cancer
|
December 2004 | Phase 2 |
| NCT04966481 | Washington University School of Medicine|Pfizer|The Joseph Sanchez Foundation |
HPV-unrelated Head and Neck Squamous Cell Carcinoma
|
April 6, 2022 | Phase 3 |
| NCT03498378 | Kathryn Gold|Pfizer|University of California, San Diego |
Head and Neck Squamous Cell Carcinoma
|
June 6, 2018 | Phase 1 |
| NCT03370276 | H. Lee Moffitt Cancer Center and Research Institute|James and Esther King Biomedical Research Program|Eli Lilly and Company|Bristol-Myers Squibb |
Squamous Cell Carcinoma of the Oropharynx|Squamous Cell Carcinoma of the Larynx|Squamous Cell Carcinoma of the Oral Cavity|Squamous Cell Carcinoma of the Hypopharynx|Squamous Cell Carcinoma of the Paranasal Sinus|Head and Neck Squamous Cell Carcinoma|Squamous Cell Cancer|Head and Neck Carcinoma
|
December 20, 2017 | Phase 1|Phase 2 |
| NCT02855086 | Eben Rosenthal|National Cancer Institute (NCI)|Stanford University |
Brain Neoplasm|Malignant Glioma
|
October 2016 | Phase 1|Phase 2 |
| NCT01614938 | Fudan University |
Nasopharyngeal Carcinoma
|
August 2010 | Phase 2 |
| NCT02716311 | Intergroupe Francophone de Cancerologie Thoracique |
Non Small Cell Lung Cancer
|
May 2016 | Phase 2 |
| NCT01020864 | Per Pfeiffer|Odense University Hospital |
Head and Neck Neoplasms
|
January 2010 | Phase 2 |
| NCT01864772 | Groupe Oncologie Radiotherapie Tete et Cou|Gustave Roussy, Cancer Campus, Grand Paris |
Metastatic or Recurrent Head and Neck Squamous Cell Cancer
|
September 2013 | Phase 2 |
| NCT04165031 | Eli Lilly and Company |
Advanced Solid Tumor|Non-Small Cell Lung Cancer|Colorectal Cancer
|
November 28, 2019 | Phase 1|Phase 2 |
| NCT03887442 | Grupo Español de Tratamiento de Tumores de Cabeza y Cuello|Merck Sharp & Dohme LLC|Pivotal S.L. |
Head and Neck Cancer
|
February 16, 2011 | Phase 2 |
| NCT00203931 | University of Chicago|Bristol-Myers Squibb |
Non-small Cell Lung Cancer
|
March 2005 | Phase 2 |
| NCT05414032 | University Health Network, Toronto|AstraZeneca|Eli Lilly and Company |
Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
|
July 2022 | Phase 2 |
| NCT03552406 | ISU Abxis Co., Ltd. |
Solid Tumor
|
April 27, 2018 | Phase 1 |
| NCT01388790 | Merck KGaA, Darmstadt, Germany |
Gastric Cancer
|
June 2011 | Phase 2 |
| NCT03391934 | Cinnagen |
Metastatic Colorectal Cancer
|
January 20, 2018 | Phase 3 |
| NCT01943786 | Sofia Perea, Director Clinical Trials Unit.|Grupo Hospital de Madrid |
Colorectal Cancer Metastatic
|
April 2013 | |
| NCT02515734 | Japan Clinical Cancer Research Organization |
Colorectal Cancer
|
August 2015 | Phase 2 |
| NCT00081302 | Radiation Therapy Oncology Group|National Cancer Institute (NCI) |
Lung Cancer
|
March 2004 | Phase 2 |
| NCT00005076 | University of Alabama at Birmingham|National Cancer Institute (NCI) |
Colorectal Cancer
|
October 1999 | Phase 2 |
| NCT00508664 | ClinAssess|Merck Sharp & Dohme LLC|Sanofi|University of Leipzig |
Squamous Cell Carcinoma of the Hypopharynx|Larynx Carcinoma
|
July 2007 | Phase 2 |
| NCT03051906 | Azienda Ospedaliero-Universitaria Careggi |
Head and Neck Neoplasms
|
January 2018 | Phase 1|Phase 2 |
| NCT00437268 | Eli Lilly and Company |
Colorectal Cancer|Colorectal Carcinoma|Colorectal Tumor
|
March 2007 | Phase 2 |
| NCT00145314 | The Nordic Colorectal Cancer Biomodulation Group |
Metastatic Colorectal Cancer
|
May 2005 | Phase 3 |
| NCT04717375 | Biond Biologics |
Cancer
|
April 11, 2021 | Phase 1|Phase 2 |
| NCT03356158 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. |
Metastatic Colorectal Cancer
|
November 15, 2017 | Phase 1 |
| NCT00361244 | Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute |
Colorectal Carcinoma
|
July 2006 | Phase 1|Phase 2 |
| NCT00336856 | University of Pittsburgh|Bristol-Myers Squibb |
Colon Cancer|Rectum Cancer
|
June 2006 | Phase 2 |
| NCT00698841 | Eli Lilly and Company |
Advanced Cancer
|
February 2009 | Phase 2 |
| NCT00881114 | Georgetown University |
Head and Neck Cancer
|
April 2009 | Phase 2 |
| NCT00778830 | Merck KGaA, Darmstadt, Germany|Merck Pte. Ltd., Singapore |
Metastatic Colorectal Cancer
|
February 2009 | Phase 1|Phase 2 |
| NCT00704639 | Trans Tasman Radiation Oncology Group |
Head and Neck Cancer
|
April 2008 | Phase 1|Phase 2 |
| NCT05312398 | University of Campania Luigi Vanvitelli |
Metastatic Colorectal Adenocarcinoma
|
July 15, 2021 | Phase 2 |
| NCT04872634 | NKMAX Co., Ltd. |
Non-small Cell Lung Cancer
|
July 8, 2021 | Phase 1|Phase 2 |
| NCT02291289 | Hoffmann-La Roche |
Colorectal Cancer
|
April 17, 2015 | Phase 2 |
| NCT03349710 | Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd |
Squamous Cell Carcinoma of the Head and Neck
|
December 15, 2017 | Phase 3 |
| NCT00448838 | University of Miami |
Pancreatic Cancer
|
May 2006 | Not Applicable |
| NCT01228734 | Merck KGaA, Darmstadt, Germany |
Metastatic Colorectal Cancer
|
September 9, 2010 | Phase 3 |
| NCT01758731 | University of Colorado, Denver |
Squamous Cell Carcinoma of the Head and Neck
|
October 22, 2012 | Phase 1 |
| NCT00894569 | Heidelberg University|Merck KGaA, Darmstadt, Germany |
Neoplasms, Unknown Primary|Carcinoma
|
July 2009 | Phase 2 |
| NCT01663259 | University of Michigan Rogel Cancer Center |
Squamous Cell Carcinoma of the Oropharynx|HPV
|
January 2011 | Not Applicable |
| NCT00227734 | Swiss Group for Clinical Cancer Research |
Colorectal Cancer
|
June 2004 | Phase 2 |
| NCT00931840 | Enzon Pharmaceuticals, Inc. |
Metastatic Colorectal Cancer
|
June 2009 | Phase 2 |
| NCT00946712 | Southwest Oncology Group|National Cancer Institute (NCI) |
Recurrent Large Cell Lung Carcinoma|Recurrent Lung Adenocarcinoma|Recurrent Squamous Cell Lung Carcinoma|Stage IV Large Cell Lung Carcinoma|Stage IV Lung Adenocarcinoma|Stage IV Squamous Cell Lung Carcinoma
|
July 15, 2009 | Phase 3 |
| NCT00833261 | University of Texas Southwestern Medical Center |
Head and Neck Cancer
|
December 2008 | Phase 2 |
| NCT00660582 | Per Pfeiffer|Odense University Hospital |
Metastatic Colorectal Cancer
|
April 2008 | Phase 2 |
| NCT05200442 | University of Chicago|Verastem, Inc. |
Colorectal Cancer|Colorectal Adenocarcinoma|Colorectal Cancer Metastatic|Advanced Colorectal Carcinoma|Advanced Colorectal Adenocarcinoma
|
August 22, 2022 | Phase 1|Phase 2 |
| NCT03944252 | Gruppo Oncologico del Nord-Ovest |
Squamous Cell Anal Carcinoma
|
September 18, 2018 | Phase 2 |
| NCT02057107 | David A. Clump, MD, PhD|University of Pittsburgh |
Recurrent|Head and Neck Cancer
|
May 2013 | Phase 2 |
| NCT00005814 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Head and Neck Cancer
|
December 1999 | Phase 2 |
| NCT00845039 | Eli Lilly and Company|NSABP Foundation Inc |
Colon Cancer|Rectal Cancer
|
May 2009 | Phase 2 |
| NCT01836653 | EPS Corporation |
Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer
|
May 2013 | Phase 2 |
| NCT00661427 | Memorial Sloan Kettering Cancer Center|Eli Lilly and Company|National Comprehensive Cancer Network |
Head and Neck|Squamous Cell Cancer
|
November 2007 | Phase 2 |
| NCT00699881 | Fudan University |
Gastric Cancer
|
May 2008 | Phase 2 |
| NCT00292955 | University of Virginia|Bristol-Myers Squibb|Eli Lilly and Company|Washington University School of Medicine |
Cancer of the Cervix
|
February 2006 | Phase 2 |
| NCT01969877 | Lund University Hospital |
Locally Advanced Head and Neck Cancer
|
November 2013 | Phase 3 |
| NCT02095054 | M.D. Anderson Cancer Center |
Advanced Cancers
|
March 19, 2014 | Phase 1 |
| NCT01301248 | Theagenio Cancer Hospital |
Head and Neck Neoplasms|AJCC Stage III+IV
|
March 2008 | Phase 2 |
| NCT00436072 | Dana-Farber Cancer Institute|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|AstraZeneca |
Colorectal Cancer
|
February 2007 | Phase 1 |
| NCT02599324 | Pharmacyclics LLC. |
Metastatic Renal Cell Carcinoma|Advanced Urothelial Carcinoma|Advanced Gastric Adenocarcinoma|Metastatic Colorectal Adenocarcinoma
|
December 1, 2015 | Phase 1|Phase 2 |
| NCT01332266 | Eisai Inc.|PharmaBio Development Inc. |
Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
|
September 19, 2011 | Phase 1|Phase 2 |
| NCT00321100 | Fox Chase Cancer Center |
Colorectal Neoplasms
|
April 12, 2006 | Phase 2 |
| NCT01230476 | University of Malaya|Merck Serono International SA |
Nasopharyngeal Carcinoma
|
May 2010 | Phase 2 |
| NCT01040832 | EMD Serono |
Squamous Cell Carcinoma of the Head and Neck Cancer
|
December 2009 | Phase 2 |
| NCT00957853 | M.D. Anderson Cancer Center|Eli Lilly and Company |
Head and Neck Squamous Cell Carcinoma
|
October 17, 2011 | Phase 2 |
| NCT01142869 | Merck KGaA, Darmstadt, Germany|Merck Ltd., India |
Carcinoma, Squamous Cell
|
December 31, 2009 | |
| NCT05019534 | West China Hospital |
BRAF V600E-mutated +MSS Metastatic Colorectal Cancer|Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody
|
August 15, 2021 | Phase 1 |
| NCT00501410 | M.D. Anderson Cancer Center|Bristol-Myers Squibb |
Colorectal Cancer
|
April 23, 2007 | Phase 1 |
| NCT00276744 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Pancreatic Cancer
|
October 2005 | Phase 2 |
| NCT00165334 | Dana-Farber Cancer Institute|Massachusetts General Hospital|Brigham and Women´s Hospital|Beth Israel Deaconess Medical Center|Bristol-Myers Squibb |
Non-small Cell Lung Cancer
|
June 2005 | Phase 2 |
| NCT02633176 | Sun Yat-sen University|Chinese Southwest Oncology Group |
Nasopharyngeal Carcinoma
|
January 2015 | Phase 3 |
| NCT00316888 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Anal Cancer
|
January 2007 | Phase 2 |
| NCT00482222 | University of Southampton|University Hospital Southampton NHS Foundation Trust |
Colorectal Cancer|Metastatic Cancer
|
February 2007 | Phase 3 |
| NCT04034459 | Ludwig-Maximilians - University of Munich |
Metastatic Colorectal Cancer
|
November 25, 2016 | Phase 2 |
| NCT01192087 | Heidelberg University|Dept. of Radiation Oncology, INF 400, 69120 Heidelberg, Germany|University Hospital Heidelberg|Merck KGaA, Darmstadt, Germany |
Adenoid Cystic Carcinoma
|
June 2012 | Phase 1|Phase 2 |
| NCT01032291 | Celgene Corporation|Celgene |
Colorectal Cancer
|
December 2009 | Phase 2 |
| NCT00467116 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) |
Pancreatic Cancer
|
October 2005 | Phase 1 |
| NCT00207077 | Eli Lilly and Company |
Neoplasms
|
August 2005 | Phase 1 |
| NCT03693612 | GlaxoSmithKline|MedImmune LLC |
Neoplasms
|
November 26, 2018 | Phase 1|Phase 2 |
| NCT00301028 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Head and Neck Cancer
|
April 2006 | Phase 2 |
| NCT02128906 | Heath Skinner|University of Pittsburgh |
Squamous Cell Carcinoma
|
December 2013 | Phase 2 |
| NCT00254137 | Ludwig-Maximilians - University of Munich|Merck Sharp & Dohme LLC|Sanofi|Pfizer|Hoffmann-La Roche |
Metastatic Colorectal Cancer
|
September 2004 | Phase 2 |
| NCT02282371 | Memorial Sloan Kettering Cancer Center|Novartis Pharmaceuticals |
Head and Neck Squamous Cell Cancer
|
October 30, 2014 | Phase 1 |
| NCT00112346 | Eli Lilly and Company |
Non-Small-Cell Lung Carcinoma
|
January 2005 | Phase 2 |
| NCT02499120 | Pfizer |
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
|
September 10, 2015 | Phase 2 |
| NCT02318901 | Western Regional Medical Center |
Advanced Cancer|Breast Cancer|Gastric Cancer|Esophageal Cancer|Colorectal Cancer
|
October 2014 | Phase 1|Phase 2 |
| NCT02404935 | UNICANCER |
Metastatic Colorectal Cancer
|
November 22, 2013 | Phase 2 |
| NCT00536614 | Gruppo Italiano per lo studio dei Carcinomi dell´Apparato Digerente|Mario Negri Institute for Pharmacological Research |
Pancreatic Cancer
|
May 2005 | Phase 2 |
| NCT00020930 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Colorectal Cancer
|
March 2001 | Phase 2 |
| NCT01326468 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Pfizer|Thomas Jefferson University |
Head and Neck Cancer
|
January 2011 | Not Applicable |
| NCT03366155 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Colorectal Cancer|Liver Metastases|Colorectal Adenocarcinoma|Colorectal Cancer With Hepatic Metastases|Colorectal Carcinoma
|
June 24, 2019 | Phase 2 |
| NCT01524978 | Hoffmann-La Roche |
Multiple Myeloma, Neoplasms
|
April 12, 2012 | Phase 2 |
| NCT00736944 | Washington University School of Medicine|Celgene Corporation |
Squamous Cell Carcinoma of the Head and Neck
|
December 19, 2008 | Phase 2 |
| NCT04065555 | Presage Biosciences|Takeda |
Head and Neck Cancer
|
October 7, 2020 | Early Phase 1 |
| NCT02707588 | Groupe Oncologie Radiotherapie Tete et Cou |
Squamous Cell Carcinoma of the Head and Neck
|
May 18, 2016 | Phase 2 |
| NCT01251536 | Universitaire Ziekenhuizen KU Leuven|Merck KGaA, Darmstadt, Germany |
Colorectal Cancer
|
December 2010 | Phase 2 |
| NCT01631539 | Universitaire Ziekenhuizen KU Leuven|Biocompatibles UK Ltd |
Liver Metastases|Colorectal Cancer
|
September 2012 | Not Applicable |
| NCT02327169 | Millennium Pharmaceuticals, Inc.|Takeda |
Advanced Nonhematologic Malignancies
|
January 14, 2015 | Phase 1 |
| NCT00215722 | Grupo de Investigacao do Cancro Digestivo |
Colorectal Carcinoma
|
July 2005 | Phase 2 |
| NCT01221753 | Dana-Farber Cancer Institute |
Squamous Cell Carcinoma of the Head and Neck|Human Papilloma Virus
|
July 2011 | Phase 2 |
| NCT00954876 | Translational Genomics Research Institute|Eli Lilly and Company |
Metastatic Colorectal Cancer
|
August 2009 | Phase 2 |
| NCT03387111 | ImmunityBio, Inc. |
Squamous Cell Carcinoma
|
January 13, 2018 | Phase 1|Phase 2 |
| NCT01874171 | University of Warwick|Cancer Research UK|University of Birmingham|University of Oxford |
Oropharyngeal Squamous Cell Carcinoma
|
November 15, 2012 | Phase 3 |
| NCT02573493 | Washington University School of Medicine|Celgene Corporation |
Squamous Cell Carcinoma of the Head and Neck|Carcinoma, Squamous Cell of the Head and Neck|Cancer of Head and Neck|Cancer of the Head and Neck|Head and Neck Cancer|Neoplasms, Head and Neck
|
April 13, 2016 | Phase 2 |
| NCT01034189 | National Taiwan University Hospital |
Esophageal Cancer
|
October 2008 | Phase 2 |
| NCT04017650 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
BRAF NP_004324.2:p.V600E|Metastatic Colon Adenocarcinoma|Metastatic Microsatellite Stable Colorectal Carcinoma|Metastatic Rectal Adenocarcinoma|Progressive Disease|Recurrent Colorectal Carcinoma|Stage III Colorectal Cancer AJCC v8|Stage IIIA Colorectal Cancer AJCC v8|Stage IIIB Colorectal Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8|Unresectable Colon Adenocarcinoma|Unresectable Rectal Adenocarcinoma
|
June 14, 2019 | Phase 1|Phase 2 |
| NCT05576896 | Northwestern University|National Cancer Institute (NCI) |
Stage IV Colorectal Cancer Positive for BRAF V600E Mutation|Colorectal Cancer|Colorectal Cancer Stage IV
|
October 10, 2022 | Phase 2 |
| NCT01432119 | M.D. Anderson Cancer Center |
Advanced Cancers
|
December 2012 | Phase 1 |
| NCT01302834 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology |
Head and Neck Cancer|Precancerous Condition
|
June 2011 | Phase 3 |
| NCT01466244 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Head and Neck Cancer
|
November 11, 2011 | |
| NCT00309179 | Eisai Inc. |
Advanced Colorectal Cancer
|
September 24, 2007 | Phase 2 |
| NCT02633800 | Daiichi Sankyo, Inc. |
Head and Neck Neoplasms
|
December 22, 2015 | Phase 2 |
| NCT00703976 | University of Pittsburgh|Eli Lilly and Company|Genentech, Inc. |
Cancer
|
October 2008 | Phase 2 |
| NCT00275951 | National Taiwan University Hospital|Taipei Veterans General Hospital, Taiwan|National Health Research Institutes, Taiwan|Chang Gung Memorial Hospital|Tri-Service General Hospital |
Gastric Cancer
|
December 2005 | Phase 2 |
| NCT01611506 | Dr Anna Dorothea Wagner|Centre Hospitalier Universitaire Vaudois |
Gastric Cancer
|
February 2012 | Phase 1|Phase 2 |
| NCT03769311 | University of Wisconsin, Madison|National Institute of Dental and Craniofacial Research (NIDCR)|American Cancer Society, Inc. |
Head and Neck Cancer|Squamous Cell Carcinoma
|
April 17, 2019 | Phase 2 |
| NCT00408564 | Medical University of South Carolina |
Pancreatic Cancer
|
January 2006 | Phase 2 |
| NCT00544362 | Federation Francophone de Cancerologie Digestive |
Esophageal Cancer
|
July 2007 | Phase 1|Phase 2 |
| NCT01602315 | Novartis Pharmaceuticals|Novartis |
Recurrent Head and Neck Squamous Cell Carcinoma|Metastatic Head and Neck Squamous Cell Carcinoma
|
November 12, 2012 | Phase 1|Phase 2 |
| NCT00622674 | Masonic Cancer Center, University of Minnesota |
Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Kidney Cancer|Lung Cancer|Pancreatic Cancer|Sarcoma|Unspecified Adult Solid Tumor, Protocol Specific
|
November 2005 | Phase 1 |
| NCT01152437 | Boehringer Ingelheim |
Colorectal Neoplasms
|
June 2010 | Phase 2 |
| NCT02753140 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University |
Carcinoma, Squamous Cell of Head and Neck
|
April 2016 | Phase 2 |
| NCT01652482 | Genentech, Inc. |
Colorectal Cancer
|
October 2012 | Phase 2 |
| NCT00096031 | Southwest Oncology Group|National Cancer Institute (NCI) |
Esophageal Cancer
|
October 2004 | Phase 2 |
| NCT04513951 | Gruppo Oncologico del Nord-Ovest |
Metastatic Colorectal Cancer
|
April 1, 2020 | Phase 2 |
| NCT01134666 | Merck KGaA, Darmstadt, Germany|Merck Ltd., India |
Colorectal Neoplasms
|
November 30, 2009 | |
| NCT04892173 | Nanobiotix |
Locally Advanced Head and Neck Squamous Cell Carcinoma
|
January 5, 2022 | Phase 3 |
| NCT04262635 | Sun Yat-sen University |
Colorectal Cancer
|
September 1, 2020 | Phase 3 |
| NCT02736578 | Eben Rosenthal|National Cancer Institute (NCI)|Stanford University |
Pancreatic Adenocarcinoma
|
July 2016 | Phase 2 |
| NCT04587128 | University of Wisconsin, Madison|Doris Duke Charitable Foundation |
Metastatic Colorectal Cancer
|
October 19, 2020 | Phase 2 |
| NCT01271439 | Sun Yat-sen University|Zhejiang Cancer Hospital|Wenzhou Medical University|The First Affiliate Hospital of Guangxi Medical College|Xijing Hospital|Hunan Cancer Hospital|Jiangxi Provincial Cancer Hospital|Wuhan Union Hospital, China|Wuhan University|Hubei Cancer Hospital|Tongji University|Affiliated Cancer Hospital of Shantou University Medical College|Shenzhen People´s Hospital|First People´s Hospital of Foshan |
Nasopharyngeal Carcinoma
|
September 2010 | Phase 2 |
| NCT00875849 | Centre Antoine Lacassagne |
Head and Neck Cancer
|
March 2008 | Phase 2 |
| NCT00439517 | Merck KGaA, Darmstadt, Germany |
Previously Untreated Metastatic Colorectal Cancer
|
February 2007 | Phase 2 |
| NCT00445861 | Swiss Group for Clinical Cancer Research |
Esophageal Cancer
|
January 2007 | Phase 1|Phase 2 |
| NCT00193453 | SCRI Development Innovations, LLC|Bristol-Myers Squibb |
Lung Cancer
|
July 2005 | Phase 2 |
| NCT03401957 | National Health Research Institutes, Taiwan|National Cheng-Kung University Hospital|Kaohsiung Medical University Chung-Ho Memorial Hospital|Taipei Veterans General Hospital, Taiwan|Cathay General Hospital |
Colorectal Cancer|Drug Resistance|Mass Spectrometry|RAS-RAF Pathway Deregulation
|
January 2018 | |
| NCT01238237 | Northwell Health |
Glioblastoma Multiforme (GBM)|ANAPLASTIC ASTROCYTOMA (AOA)|GBM|Anaplastic Astrocytoma
|
December 2009 | Phase 1 |
| NCT04718038 | Henan Cancer Hospital |
Wild-type KRAS,NRAS and BRAF V600E Metastatic Colorectal Cancer
|
July 1, 2016 | |
| NCT04831528 | Fudan University |
Metastatic Colorectal Cancer
|
April 10, 2021 | |
| NCT04515394 | EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono |
Colorectal Neoplasms
|
January 28, 2021 | Phase 2 |
| NCT00611858 | Dana-Farber Cancer Institute|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Brigham and Women´s Hospital|Bristol-Myers Squibb |
Rectal Cancer
|
May 2008 | Phase 2 |
| NCT02836847 | Shanghai Jiao Tong University School of Medicine|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Ruijin Hospital|RenJi Hospital|Eastern Hepatobiliary Surgery Hospital|Huashan Hospital |
Cholangiocarcinoma of the Extrahepatic Bile Duct|Gallbladder Cancer
|
July 2016 | Phase 2 |
| NCT02014831 | Centre Leon Berard |
Squamous Cell Carcinoma of the Penis
|
February 2016 | Phase 2 |
| NCT00101348 | National Cancer Institute (NCI) |
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Colon Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Pancreatic Cancer|Recurrent Rectal Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage III Adenoid Cystic Carcinoma of the Oral Cavity|Stage III Basal Cell Carcinoma of the Lip|Stage III Colon Cancer|Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage III Lymphoepithelioma of the Nasopharynx|Stage III Lymphoepithelioma of the Oropharynx|Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage III Mucoepidermoid Carcinoma of the Oral Cavity|Stage III Pancreatic Cancer|Stage III Rectal Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage III Verrucous Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Oral Cavity|Stage IIIB Non-small Cell Lung Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Basal Cell Carcinoma of the Lip|Stage IV Colon Cancer|Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Lymphoepithelioma of the Oropharynx|Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Pancreatic Cancer|Stage IV Rectal Cancer|Stage IV Renal Cell Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Untreated Metastatic Squamous Neck Cancer With Occult Primary
|
January 2005 | Phase 1|Phase 2 |
| NCT00327093 | Hospices Civils de Lyon |
Colorectal Cancer|Neoplasm Metastasis
|
May 2006 | Phase 4 |
| NCT00614393 | Merck Sharp & Dohme LLC |
Metastatic Colorectal Cancer
|
December 24, 2007 | Phase 2 |
| NCT02177838 | Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey |
Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Verrucous Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Verrucous Carcinoma of the Larynx|Tongue Cancer
|
March 25, 2015 | Not Applicable |
| NCT01292356 | Poitiers University Hospital |
Metastatic Colon Cancer
|
December 20, 2010 | Phase 2 |
| NCT01468896 | National Cancer Institute (NCI) |
Metastatic Head and Neck Squamous Cell Carcinoma|Recurrent Head and Neck Squamous Cell Carcinoma|Unresectable Head and Neck Squamous Cell Carcinoma
|
October 26, 2011 | Phase 1|Phase 2 |
| NCT03126708 | Peking University |
Esophageal Cancer, Squamous Cell|Cetuximab Effect|Chemotherapy Effect
|
April 10, 2017 | Phase 2 |
| NCT01087970 | Eli Lilly and Company |
Head and Neck Neoplasms
|
August 2010 | Phase 2 |
| NCT02845856 | Fuda Cancer Hospital, Guangzhou|Shenzhen Hank Bioengineering Institute |
Recurrent Non-small Cell Lung Cancer
|
July 1, 2016 | Phase 1|Phase 2 |
| NCT00689624 | University Hospital of Crete |
Metastatic Colorectal Cancer
|
July 2007 | Phase 2 |
| NCT00513266 | Centre Hospitalier Universitaire Vaudois|National Cancer Institute (NCI) |
Colorectal Cancer|Metastatic Cancer
|
June 2007 | Phase 2 |
| NCT04590963 | AstraZeneca|Innate Pharma |
Squamous Cell Carcinoma of the Head and Neck
|
October 2, 2020 | Phase 3 |
| NCT00660218 | State University of New York - Upstate Medical University|CTI BioPharma |
Carcinoma, Squamous Cell
|
March 2008 | Phase 1|Phase 2 |
| NCT00063388 | Eli Lilly and Company|Bristol-Myers Squibb |
Non-Small-Cell Lung Cancer
|
May 2003 | Phase 2 |
| NCT04833036 | Fudan University |
Colorectal Cancer
|
October 1, 2019 | Phase 2 |
| NCT03362684 | IntegraGen SA|Federation Francophone de Cancerologie Digestive|Exystat |
Colorectal Cancer
|
November 2005 | Phase 3 |
| NCT01488318 | Julie E. Bauman, MD, MPH|Bristol-Myers Squibb|University of Pittsburgh |
Squamous Cell Carcinoma Of The Head And Neck
|
September 2011 | Phase 2 |
| NCT01079780 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Colorectal Cancer
|
October 8, 2010 | Phase 2 |
| NCT01577173 | Genentech, Inc. |
Head and Neck Cancer
|
July 2012 | Phase 2 |
| NCT00556413 | Institut du Cancer de Montpellier - Val d´Aurelle |
Colorectal Cancer
|
September 2005 | Phase 2 |
| NCT01217450 | National Cancer Institute (NCI) |
Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer|Unspecified Adult Solid Tumor, Protocol Specific
|
October 2012 | Phase 1 |
| NCT00251485 | Veeda Oncology|Bristol-Myers Squibb|Sanofi |
Colorectal Cancer
|
March 2004 | Phase 2 |
| NCT02551159 | AstraZeneca |
Squamous Cell Carcinoma of the Head and Neck
|
October 15, 2015 | Phase 3 |
| NCT02205398 | Novartis Pharmaceuticals|Novartis |
Squamous Cell Carcinoma of Head and Neck (SCCHN)|Metastatic Colorectal Cancer
|
July 28, 2014 | Phase 1 |
| NCT05291156 | University of Campania Luigi Vanvitelli |
Metastatic Colorectal Cancer
|
July 21, 2022 | Phase 2 |
| NCT01276379 | Grupo Espanol Multidisciplinario del Cancer Digestivo |
Colorectal Cancer
|
January 2011 | Phase 2 |
| NCT03024489 | Mahidol University |
Head and Neck Cancer|Locally Advanced
|
July 19, 2017 | Phase 1|Phase 2 |
| NCT01540682 | Abramson Cancer Center of the University of Pennsylvania |
Head and Neck Cancer
|
February 2012 | Phase 1 |
| NCT01834014 | EPS Corporation |
Liver Metastasis|Colorectal Cancer
|
May 2013 | Not Applicable |
| NCT02123381 | Sichuan Cancer Hospital and Research Institute|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|Affiliated Cancer Hospital & Institute of Guangzhou Medical University|Southwest Hospital, China|Xinqiao Hospital of Chongqing |
Locally Advanced Thoracic Middle-lower Segment Esophageal Squamous Cell Carcinoma
|
April 2014 | Phase 2 |
| NCT05039177 | Erasca, Inc. |
Metastatic Colorectal Cancer
|
September 20, 2021 | Phase 1|Phase 2 |
| NCT02490436 | Sorlandet Hospital HF|Frontier Science & Technology Research Foundation, Inc.|Merck KGaA, Darmstadt, Germany |
Neuralgia|Complex Regional Pain Syndromes
|
October 2015 | Phase 2 |
| NCT00906360 | National Cancer Institute (NCI) |
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage III Verrucous Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Oral Cavity|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary
|
July 2008 | Phase 1 |
| NCT05382559 | Astellas Pharma Inc |
Solid Tumor
|
June 8, 2022 | Phase 1 |
| NCT00835679 | National Cancer Institute (NCI) |
Liver Metastases|Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IV Colon Cancer|Stage IV Rectal Cancer
|
December 2009 | Early Phase 1 |
| NCT03082534 | University of California, San Diego|Merck Sharp & Dohme LLC |
HNSCC|Lip SCC|Oral Cavity Cancer|Oropharynx Cancer|Larynx Cancer|Hypopharynx Cancer|Nasopharynx Cancer|Sinonasal Carcinoma|Cutaneous Squamous Cell Carcinoma|Head and Neck Neoplasms|Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma
|
March 28, 2017 | Phase 2 |
| NCT01712919 | Jiangsu Cancer Institute & Hospital |
Nasopharyngeal Carcinoma
|
May 2010 | Phase 1|Phase 2 |
| NCT00791141 | Heinrich-Heine University, Duesseldorf |
Head and Neck Cancer
|
August 2008 | Phase 2 |
| NCT04929223 | Hoffmann-La Roche |
Metastatic Colorectal Cancer
|
October 22, 2021 | Phase 1 |
| NCT00079066 | NCIC Clinical Trials Group|Australasian Gastro-Intestinal Trials Group|Canadian Cancer Trials Group |
Colorectal Cancer|Quality of Life
|
August 28, 2003 | Phase 3 |
| NCT01451632 | Merrimack Pharmaceuticals|Sanofi |
Colorectal Cancer|Squamous Cell Head and Neck Cancer|Non-small Cell Lung Cancer|Triple Negative Breast Cancer|Other Tumors With EGFR Dependence
|
October 2011 | Phase 1 |
| NCT00275041 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Breast Cancer
|
February 2006 | Phase 2 |
| NCT02861898 | Northwell Health |
Glioblastoma|Brain Cancer|Brain Neoplasm|Brain Tumor|Brain Neoplasm, Malignant|EGFR Gene Overexpression|GBM
|
June 2016 | Phase 1|Phase 2 |
| NCT05160896 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Advanced Metastatic Colorectal Cancer
|
November 12, 2021 | Phase 2 |
| NCT04509635 | Fudan University |
Colorectal Cancer|Liver Metastases|Cetuximab
|
September 1, 2020 | Phase 3 |
| NCT00939627 | National Cancer Institute (NCI) |
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary
|
July 2009 | Phase 2 |
| NCT00100841 | National Cancer Institute (NCI) |
Adenocarcinoma of the Rectum|Mucinous Adenocarcinoma of the Colon|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Stage IV Colon Cancer|Stage IV Rectal Cancer
|
November 2004 | Phase 2 |
| NCT01154920 | M.D. Anderson Cancer Center|Dana-Farber Cancer Institute |
Head and Neck Squamous Cell Carcinoma
|
July 2010 | Phase 2 |
| NCT01309126 | HiberCell, Inc. |
Colorectal Cancer
|
April 2011 | Phase 3 |
| NCT02857270 | Eli Lilly and Company |
Advanced Cancer|Metastatic Melanoma|Metastatic Non-small Cell Lung Cancer|Colorectal Cancer
|
September 29, 2016 | Phase 1 |
| NCT01166035 | Medical University Innsbruck|Celgene Corporation|Innsbruck - Tyrolean Working Group of Experimental Oncology (TEXO) |
Solid Tumors
|
March 2010 | Phase 1|Phase 2 |
| NCT01482377 | Hoffmann-La Roche |
Neoplasms
|
December 2011 | Phase 1 |
| NCT00895362 | M.D. Anderson Cancer Center |
Advanced Cancers
|
April 2009 | Phase 1 |
| NCT00115518 | Heidelberg University |
Carcinoma, Non-Small-Cell Lung
|
May 2005 | Phase 2 |
| NCT02052960 | Glycotope GmbH |
Carcinoma, Squamous Cell of Head and Neck
|
February 2014 | Phase 2 |
| NCT02316496 | GERCOR - Multidisciplinary Oncology Cooperative Group |
Colorectal Cancer Metastatic
|
September 23, 2015 | Phase 2 |
| NCT00086892 | Gynecologic Oncology Group|National Cancer Institute (NCI)|Bristol-Myers Squibb|GOG Foundation |
Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
June 2004 | Phase 2 |
| NCT00518193 | ARCAGY+ GINECO GROUP |
Cervix Cancer
|
April 2007 | Phase 2 |
| NCT01810913 | National Cancer Institute (NCI)|NRG Oncology |
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma|Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
|
March 18, 2013 | Phase 2|Phase 3 |
| NCT01133665 | University of Chicago|Celgene Corporation |
Squamous Cell Carcinoma
|
February 2010 | Phase 2 |
| NCT01012609 | Memorial Sloan Kettering Cancer Center|Children´s Healthcare of Atlanta|Dana-Farber Cancer Institute|M.D. Anderson Cancer Center|Phoenix Children´s Hospital|Alberta Children´s Hospital|University of Colorado, Denver|Seattle Children´s Hospital|Johns Hopkins University|Children´s Mercy Hospital Kansas City|University of Florida |
Brain Cancer
|
October 30, 2009 | Phase 2 |
| NCT03646461 | University of California, San Diego|Pharmacyclics LLC. |
Head and Neck Cancer|Squamous Cell Carcinoma of the Head and Neck
|
October 17, 2018 | Phase 2 |
| NCT00362102 | Eli Lilly and Company |
Colorectal Carcinoma
|
October 2005 | Phase 2 |
| NCT01225744 | The Christie NHS Foundation Trust|Merck Sharp & Dohme LLC |
Metastatic Colorectal Cancer
|
April 2009 | Phase 2 |
| NCT01696955 | National Cancer Institute (NCI) |
Head and Neck Squamous Cell Carcinoma|Recurrent Head and Neck Carcinoma
|
August 20, 2012 | Phase 2 |
| NCT04793958 | Mirati Therapeutics Inc. |
Advanced Colorectal Cancer|Metastatic Colorectal Cancer
|
March 15, 2021 | Phase 3 |
| NCT02507154 | National University Hospital, Singapore |
Nasopharyngeal Cancer|Head and Neck Squamous Cell Carcinoma
|
July 2015 | Phase 1|Phase 2 |
| NCT02054442 | Radboud University Medical Center|Merck Serono International SA|Leiden University Medical Center|Academisch Ziekenhuis Maastricht|Erasmus Medical Center|Medisch Spectrum Twente|Medical Center Haaglanden|Elisabeth-TweeSteden Ziekenhuis|Medical Centre Leeuwarden |
Squamous Cell Carcinoma of the Head and Neck
|
August 2016 | Phase 1|Phase 2 |
| NCT00125034 | Merck KGaA, Darmstadt, Germany |
Neoplasm Metastasis|Colorectal Cancer
|
July 2005 | Phase 2 |
| NCT00226239 | University of Pittsburgh|Bristol-Myers Squibb |
Cancer
|
October 2005 | Phase 2 |
| NCT02979977 | Yale University|National Comprehensive Cancer Network|Boehringer Ingelheim |
Squamous Cell Cancers of the Head and Neck
|
March 24, 2017 | Phase 2 |
| NCT05061420 | Sanofi |
Squamous Cell Carcinoma of Head and Neck
|
October 8, 2021 | Phase 2 |
| NCT00571740 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Colorectal Cancer
|
Phase 2 | |
| NCT01566435 | Washington University School of Medicine|Celgene |
Head and Neck Neoplasms
|
August 9, 2012 | Phase 2 |
| NCT01161316 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) |
Metastatic Colorectal Cancer
|
August 2010 | Phase 2 |
| NCT00353457 | Abramson Cancer Center of the University of Pennsylvania|Bristol-Myers Squibb|Roche Pharma AG |
Rectal Cancer
|
February 2006 | Phase 2 |
| NCT02713373 | Roswell Park Cancer Institute|National Cancer Institute (NCI)|Merck Sharp & Dohme LLC |
Recurrent Colorectal Carcinoma|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer
|
August 5, 2016 | Phase 1|Phase 2 |
| NCT00551421 | National Cancer Institute (NCI) |
Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage III Colon Cancer|Stage III Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer
|
October 2007 | Phase 1|Phase 2 |
| NCT00655876 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology |
Esophageal Cancer
|
June 2008 | Phase 3 |
| NCT01640444 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Roche Pharma AG |
Colorectal Cancer Metastatic
|
July 2012 | Phase 2 |
| NCT00425425 | Technical University of Munich |
Esophageal Cancer
|
July 2006 | Phase 1|Phase 2 |
| NCT01077986 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
Metastatic Pancreatic Cancer
|
August 2009 | Phase 1|Phase 2 |
| NCT00397904 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Esophageal Cancer|Gastric Cancer
|
October 2006 | Phase 2 |
| NCT02164916 | Southwest Oncology Group|National Cancer Institute (NCI)|Roche-Genentech |
Colorectal Cancer
|
November 2014 | Phase 2 |
| NCT01315990 | Dr. Carl Schimanski|Johannes Gutenberg University Mainz |
Colorectal Cancer Metastatic
|
January 2011 | Phase 4 |
| NCT03783403 | Celgene |
Neoplasms
|
February 1, 2019 | Phase 1 |
| NCT00599833 | The Christie NHS Foundation Trust|National Cancer Institute (NCI) |
Pancreatic Cancer
|
May 2007 | Phase 2 |
| NCT00645593 | University of Michigan Rogel Cancer Center|National Comprehensive Cancer Network|Bristol-Myers Squibb|Eli Lilly and Company |
Bladder Cancer
|
March 2008 | Phase 2 |
| NCT01960023 | NSABP Foundation Inc |
Colorectal Cancer
|
October 2013 | Phase 1|Phase 2 |
| NCT03342352 | Incyte Corporation|Bristol-Myers Squibb |
Head and Neck Cancer
|
December 15, 2017 | Phase 3 |
| NCT01287130 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Colonic Neoplasms|Cancer of the Colon|Colon Cancer|Colon Neoplasms|Colonic Cancer
|
January 7, 2011 | Phase 1 |
| NCT03493048 | Sun Yat-sen University |
Colo-rectal Cancer|Liver Metastases
|
January 1, 2018 | Phase 2 |
| NCT01360086 | Federation Francophone de Cancerologie Digestive |
Adenocarcinoma of the Gastroesophageal Junction|Gastric Cancer
|
June 2011 | Phase 2 |
| NCT00686166 | Southwest Oncology Group|National Cancer Institute (NCI) |
Colorectal Cancer
|
February 2009 | Phase 2 |
| NCT02063529 | Sun Yat-sen University |
Metastatic Colorectal Cancer
|
February 2014 | Phase 2 |
| NCT03727763 | Shanghai Changzheng Hospital |
Colorectal Cancer
|
October 8, 2018 | Phase 2 |
| NCT03109158 | NanoCarrier Co., Ltd. |
Carcinoma, Squamous Cell of Head and Neck
|
March 1, 2017 | Phase 1|Phase 2 |
| NCT00533949 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|North Central Cancer Treatment Group|Cancer and Leukemia Group B|NRG Oncology |
Lung Cancer|Radiation Toxicity
|
November 2007 | Phase 3 |
| NCT02110082 | Bristol-Myers Squibb |
Colorectal Cancer|Head and Neck Cancer
|
April 2014 | Phase 1 |
| NCT00537823 | Washington University School of Medicine |
Colorectal Cancer|Metastases
|
June 2007 | Phase 2 |
| NCT00519831 | UNC Lineberger Comprehensive Cancer Center|Bristol-Myers Squibb |
Lung Cancer
|
August 2007 | Phase 2 |
| NCT05619172 | SOTIO Biotech AG|SOTIO Biotech |
Colorectal Cancer
|
November 2022 | Phase 2 |
| NCT01109524 | Eli Lilly and Company |
Lung Neoplasms|Carcinoma|Cancer of the Lung|Non-Small-Cell Lung Carcinoma
|
July 2010 | Phase 2 |
| NCT00633464 | R-Pharm |
Triple Negative Locally Advanced Non-resectable Breast Cancer|Metastatic Breast Cancer
|
June 2008 | Phase 2 |
| NCT02438722 | Southwest Oncology Group|National Cancer Institute (NCI) |
Recurrent Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer
|
March 25, 2015 | Phase 2|Phase 3 |
| NCT01004159 | Roswell Park Cancer Institute|Bristol-Myers Squibb |
Colorectal Cancer
|
September 2009 | Phase 2 |
| NCT04561336 | University of Campania Luigi Vanvitelli |
Metastatic Colorectal Cancer|RAS Wild Type
|
August 10, 2018 | Phase 2 |
| NCT01435252 | University of Zurich |
Oropharyngeal Cancer|Hypopharyngeal Cancer|Laryngeal Cancer
|
September 19, 2011 | Phase 2 |
| NCT00483405 | UNC Lineberger Comprehensive Cancer Center|Sanofi|Roche Pharma AG|Bristol-Myers Squibb|National Center for Research Resources (NCRR)|National Cancer Institute (NCI) |
Liver Cancer
|
October 2006 | Phase 2 |
| NCT03284502 | Hanmi Pharmaceutical Company Limited |
Locally Advanced Solid Tumor|Metastatic Solid Tumor
|
May 22, 2017 | Phase 1 |
| NCT00104910 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Small Cell Carcinoma|Cervical Squamous Cell Carcinoma|Stage IB Cervical Cancer|Stage IIA Cervical Cancer|Stage IIB Cervical Cancer|Stage III Cervical Cancer|Stage IVA Cervical Cancer
|
January 2005 | Phase 1 |
| NCT02383966 | Merck KGaA, Darmstadt, Germany |
Carcinoma, Squamous Cell of Head and Neck
|
July 31, 2015 | Phase 3 |
| NCT04607421 | Pfizer|Ono Pharmaceutical Co. Ltd|Merck KGaA, Darmstadt, Germany |
Neoplasms
|
December 21, 2020 | Phase 3 |
| NCT04449874 | Genentech, Inc. |
Non-Small Cell Lung Cancer|Colorectal Cancer|Advanced Solid Tumors
|
July 29, 2020 | Phase 1 |
| NCT01084083 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Head and Neck Cancer|Precancerous Condition
|
March 2010 | Phase 2 |
| NCT00408499 | University of California, Davis|National Cancer Institute (NCI) |
Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific
|
August 2006 | Phase 1|Phase 2 |
| NCT01316757 | Fox Chase Cancer Center|National Cancer Institute (NCI) |
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary
|
February 16, 2011 | Phase 2 |
| NCT04508816 | Fudan University |
Nasopharyngeal Carcinoma
|
January 1, 2016 | Phase 2 |
| NCT05253651 | Seagen Inc.|Merck Sharp & Dohme LLC |
Colorectal Neoplasms
|
November 30, 2022 | Phase 3 |
| NCT00570674 | Dana-Farber Cancer Institute|Celgene Corporation |
Squamous Cell Carcinoma of the Head and Neck|Basaloid Squamous Cell Carcinoma|Undifferentiated Carcinoma|Adenosquamous Cell Carcinoma
|
November 2007 | Phase 1|Phase 2 |
| NCT00671437 | Washington University School of Medicine |
Carcinoma, Squamous Cell
|
June 2008 | Phase 2 |
| NCT00109850 | Southwest Oncology Group|National Cancer Institute (NCI) |
Esophageal Cancer
|
May 2005 | Phase 2 |
| NCT01334177 | University of Washington|National Cancer Institute (NCI) |
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage III Verrucous Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Oral Cavity|Stage IV Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Tongue Cancer
|
June 2011 | Phase 1 |
| NCT00957411 | Institut Curie |
Cervical Cancer
|
March 2009 | Phase 2 |
| NCT02215720 | Gustave Roussy, Cancer Campus, Grand Paris |
Patients With Advanced or Metastatic Solid Tumors
|
April 2011 | Phase 1 |
| NCT00297128 | Austrian Breast & Colorectal Cancer Study Group|Hoffmann-La Roche|Merck Gesellschaft mbH, Austria |
Rectal Cancer
|
October 2005 | Phase 2 |
| NCT02277197 | James J Lee|AVEO Pharmaceuticals, Inc.|University of Pittsburgh |
Carcinoma, Squamous Cell of Head and Neck|Squamous Cell Carcinoma of the Head and Neck|Squamous Cell Carcinoma, Head And Neck
|
August 2015 | Phase 1 |
| NCT01830556 | Karolinska University Hospital |
Squamous Cell Carcinoma of the Head and Neck
|
November 2011 | Phase 2 |
| NCT00082212 | Eli Lilly and Company|Bristol-Myers Squibb |
Ovarian Cancer
|
November 2004 | Phase 2 |
| NCT00208546 | Dutch Colorectal Cancer Group|Koningin Wilhelmina Fonds|Sanofi|Roche Pharma AG|Immunicon |
Colorectal Cancer
|
June 2005 | Phase 3 |
| NCT01015664 | University of Tennessee Cancer Institute|National Comprehensive Cancer Network |
Squamous Cell Carcinoma of the Head and Neck
|
February 2010 | Phase 1|Phase 2 |
| NCT01252628 | Cascadian Therapeutics Inc.|Seagen Inc. |
Incurable Metastatic Colorectal Carcinoma|Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
|
December 2010 | Phase 1|Phase 2 |
| NCT02999087 | Groupe Oncologie Radiotherapie Tete et Cou|UNICANCER |
HNSCC
|
September 14, 2017 | Phase 3 |
| NCT00097227 | Eli Lilly and Company|Bristol-Myers Squibb |
Non-small Cell Lung Cancer
|
November 2004 | Phase 2 |
| NCT03727061 | Roswell Park Cancer Institute|National Cancer Institute (NCI) |
Recurrent Head and Neck Carcinoma|Locally Advanced Head and Neck Carcinoma
|
July 10, 2019 | Phase 2 |
| NCT01884740 | Weill Medical College of Cornell University |
Glioblastoma Multiforme|Fibrillary Astrocytoma of Brain|Glioma of Brainstem|Anaplastic Astrocytoma|Pilomyxoid Astrocytoma|Mixed Oligodendroglioma-Astrocytoma|Brain Stem Glioma|Diffuse Intrinsic Pontine Glioma
|
June 2013 | Phase 1|Phase 2 |
| NCT00103207 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Lung Cancer
|
August 2005 | Phase 2 |
| NCT00468169 | University of Chicago|Bristol-Myers Squibb |
Head and Neck Cancer
|
July 2006 | Phase 2 |
| NCT00522886 | Maastricht Radiation Oncology|Academisch Ziekenhuis Maastricht|Merck Sharp & Dohme LLC |
Non-small Cell Lung Cancer
|
April 2007 | Phase 1 |
| NCT00599131 | University of Michigan Rogel Cancer Center |
Cancer of Larynx
|
August 2007 | Phase 2 |
| NCT01790516 | Georgetown University |
Head and Neck Squamous Cell Cancer
|
May 2012 | Not Applicable |
| NCT05074966 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Colo-rectal Cancer
|
September 6, 2021 | Phase 3 |
| NCT04648189 | The Netherlands Cancer Institute|Dutch Cancer Society |
Lung Cancer|Surgery|Circulating Tumor Cell
|
January 1, 2022 | Phase 2 |
| NCT00232505 | UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)|Bristol-Myers Squibb|Avon Foundation|National Center for Research Resources (NCRR) |
Breast Cancer
|
November 2005 | Phase 2 |
| NCT02563002 | Merck Sharp & Dohme LLC |
Colorectal Carcinoma
|
November 30, 2015 | Phase 3 |
| NCT03319459 | Fate Therapeutics |
HER2 Positive Gastric Cancer|Colorectal Cancer|Head and Neck Squamous Cell Carcinoma|EGFR Positive Solid Tumor|Advanced Solid Tumors|HER2-positive Breast Cancer|Hepatocellular Carcinoma|Non Small Cell Lung Cancer|Renal Cell Carcinoma|Pancreatic Cancer|Melanoma
|
January 18, 2018 | Phase 1 |
| NCT02350712 | Daiichi Sankyo, Inc. |
Squamous Cell Carcinoma of the Head and Neck
|
December 2014 | Phase 1 |
| NCT00842712 | Merck KGaA, Darmstadt, Germany |
Carcinoma, Non-Small-Cell Lung
|
February 2009 | Phase 2 |
| NCT00593060 | Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Wyeth is now a wholly owned subsidiary of Pfizer |
Colorectal Cancer|Colorectal Adenocarcinoma
|
October 2007 | Phase 1 |
| NCT00874848 | HiberCell, Inc. |
NSCLC
|
August 2009 | Phase 2 |
| NCT03001570 | European Institute of Oncology |
Carcinoma of the Head and Neck
|
January 2014 | Phase 2 |
| NCT01107639 | Swiss Group for Clinical Cancer Research |
Adenocarcinoma of the Gastroesophageal Junction|Esophageal Cancer
|
May 27, 2010 | Phase 3 |
| NCT00591149 | University of Kansas Medical Center|Sanofi |
Head and Neck Cancer|Carcinoma, Squamous
|
June 2007 | Phase 2 |
| NCT00673738 | H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb |
Lung Cancer
|
April 2008 | Phase 2 |
| NCT02643550 | Innate Pharma|AstraZeneca |
Head and Neck Neoplasms
|
December 2015 | Phase 1|Phase 2 |
| NCT03358472 | Incyte Corporation|Merck Sharp & Dohme LLC |
Head and Neck Cancer
|
December 1, 2017 | Phase 3 |
| NCT00075686 | Southwest Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B|NCIC Clinical Trials Group |
Pancreatic Cancer
|
January 2004 | Phase 3 |
| NCT00240682 | Centre Hospitalier of Chartres|Hospital of Chartres- France |
Skin Diseases|Carcinoma, Squamous Cell
|
October 2005 | Phase 2 |
| NCT05194995 | Jacobio Pharmaceuticals Co., Ltd. |
Advanced Colorectal Cancer|Small Intestinal Cancer|Appendiceal Cancer
|
February 17, 2022 | Phase 1|Phase 2 |
| NCT00503685 | Eli Lilly and Company |
Colorectal Cancer
|
June 2007 | Phase 2 |
| NCT05022030 | West China Hospital|First Affiliated Hospital of Chongqing Medical University |
Colo-rectal Cancer|Capecitabine|Cetuximab
|
July 21, 2021 | Phase 2 |
| NCT02101034 | Washington University School of Medicine|Pfizer |
Carcinoma, Squamous Cell of Head and Neck
|
June 17, 2014 | Phase 1|Phase 2 |
| NCT04790448 | Sun Yat-sen University |
Colorectal Cancer Metastatic
|
July 27, 2020 | Phase 1|Phase 2 |
| NCT00383149 | R-Pharm |
Metastatic Pancreatic Cancer
|
January 2007 | Phase 2 |
| NCT05167409 | Criterium, Inc.|ALX Oncology Inc.|Merck Sharp & Dohme LLC|Eli Lilly and Company |
Microsatellite Stable Metastatic Colorectal Cancer
|
August 1, 2022 | Phase 2 |
| NCT02292758 | Academic and Community Cancer Research United|National Cancer Institute (NCI) |
Colorectal Adenocarcinoma|RAS Wild Type|Stage IV Colorectal Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7
|
December 12, 2014 | Phase 2 |
| NCT01925274 | Pfizer |
Metastatic Colorectal Cancer
|
November 15, 2013 | Phase 2 |
| NCT00112294 | Eli Lilly and Company |
Non-Small-Cell Lung Carcinoma
|
December 2004 | Phase 3 |
| NCT00326911 | Eli Lilly and Company |
Metastatic Pancreatic Cancer
|
May 2006 | Phase 2 |
| NCT03457896 | NSABP Foundation Inc|Puma Biotechnology, Inc. |
Metastatic Colorectal Cancer
|
May 18, 2018 | Phase 2 |
| NCT00265850 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Southwest Oncology Group|Bristol-Myers Squibb|Aptuit Inc. |
Colorectal Cancer
|
November 2005 | Phase 3 |
| NCT05040568 | M.D. Anderson Cancer Center |
Colon Cancer|Resected Stage
|
February 28, 2022 | Phase 1 |
| NCT05308446 | National Cancer Institute (NCI) |
Metastatic Colon Adenocarcinoma|Metastatic Rectal Adenocarcinoma|Stage III Colon Cancer AJCC v8|Stage III Rectal Cancer AJCC v8|Stage IV Colon Cancer AJCC v8|Stage IV Rectal Cancer AJCC v8|Unresectable Colon Adenocarcinoma|Unresectable Rectal Adenocarcinoma
|
June 6, 2022 | Phase 2 |
| NCT00338039 | M.D. Anderson Cancer Center|Bristol-Myers Squibb |
Pancreatic Cancer
|
September 2005 | Phase 2 |
| NCT00559741 | Institut Cancerologie de l´Ouest|National Cancer Institute (NCI) |
Colorectal Cancer
|
October 2005 | Phase 2 |
| NCT00162318 | Eli Lilly and Company |
Non-Small-Cell Lung Carcinoma
|
March 2005 | Phase 1 |
| NCT00406302 | Wolfgang Hilbe|Merck Sharp & Dohme LLC|Sanofi|TAKO - Tiroler Arbeitskreis Onkologie|Medical University of Vienna |
Carcinoma, Non-small-cell Lung
|
January 2007 | Phase 2 |
| NCT00738868 | Centre Oscar Lambret|National Cancer Institute (NCI) |
Head and Neck Cancer
|
October 2007 | Phase 2 |
| NCT01437449 | Stanford University |
Head and Neck Cancer
|
October 2011 | Phase 2 |
| NCT00083720 | Eli Lilly and Company|Bristol-Myers Squibb |
Colorectal Neoplasms|Metastases|Neoplasm
|
October 2004 | Phase 2 |
| NCT00367250 | Medical University of Vienna |
Metastatic Breast Cancer
|
July 2006 | Phase 1 |
| NCT00531115 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Merck Sharp & Dohme LLC |
Metastatic Colorectal Cancer
|
November 2007 | Phase 2 |
| NCT00077298 | National Cancer Institute (NCI) |
Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer
|
December 2003 | Phase 2 |
| NCT01442935 | UNICANCER |
Colorectal Cancer
|
February 2011 | Phase 2 |
| NCT00509561 | Wales Cancer Trials Unit|Cancer Research UK |
Esophageal Cancer
|
February 2008 | Phase 2|Phase 3 |
| NCT00343291 | Eli Lilly and Company |
Non-Small Cell Lung Cancer
|
December 2006 | Phase 2 |
| NCT01075841 | Merck KGaA, Darmstadt, Germany |
Neoplasms, Squamous Cell
|
March 2009 | |
| NCT01552434 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Advanced Malignant Neoplasm|Castleman Disease|Digestive System Carcinoma|Erdheim-Chester Disease|Lip and Oral Cavity Carcinoma|Lymphangioleiomyomatosis|Malignant Endocrine Neoplasm|Malignant Female Reproductive System Neoplasm|Malignant Male Reproductive System Neoplasm|Malignant Neoplasm|Malignant Respiratory Tract Neoplasm|Malignant Thoracic Neoplasm|Malignant Urinary System Neoplasm|Mesothelial Neoplasm|Metastatic Malignant Neoplasm|Metastatic Urothelial Carcinoma|Neurofibromatosis Type 2|Recurrent Adult Soft Tissue Sarcoma|Recurrent Breast Carcinoma|Recurrent Childhood Soft Tissue Sarcoma|Recurrent Digestive System Carcinoma|Recurrent Female Reproductive System Carcinoma|Recurrent Male Reproductive System Carcinoma|Recurrent Malignant Neoplasm|Recurrent Pharyngeal Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Malignant Neoplasm|Soft Tissue Neoplasm|Stage III Breast Cancer AJCC v7|Stage III Pharyngeal Cancer|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Pharyngeal Cancer|Stage IVA Pharyngeal Cancer|Stage IVB Pharyngeal Cancer|Stage IVC Pharyngeal Cancer|Thyroid Gland Neoplasm
|
March 16, 2012 | Phase 1 |
| NCT05217069 | Ludwig-Maximilians - University of Munich|Merck KGaA, Darmstadt, Germany|ClinAssess GmbH |
Treatment Related Cancer
|
September 27, 2019 | Phase 2 |
| NCT01787500 | M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Genentech, Inc. |
BRAF NP_004324.2:p.V600X|KRAS wt Allele|Metastatic Malignant Solid Neoplasm|Stage IV Colorectal Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7|Unresectable Solid Neoplasm
|
February 15, 2013 | Phase 1 |
| NCT00735345 | Arbeitsgemeinschaft medikamentoese Tumortherapie|Merck Sharp & Dohme LLC|Sanofi |
Esophageal Cancer
|
August 2008 | Phase 2 |
| NCT01237483 | Groupe Oncologie Radiotherapie Tete et Cou |
Head and Neck Cancer Squamous Cell
|
October 2010 | Phase 2 |
| NCT01289522 | Groupe Oncologie Radiotherapie Tete et Cou|Gustave Roussy, Cancer Campus, Grand Paris |
Squamous Cell Head and Neck Carcinoma|Recurrent or Metastatic Disease
|
September 2009 | Phase 2 |
| NCT00766220 | M.D. Anderson Cancer Center|Sirtex Medical |
Colon Cancer|Colorectal Cancer
|
October 2009 | Phase 2 |
| NCT01871311 | Georgetown University|Novartis |
Colorectal Cancer|Head and Neck Cancer
|
May 2014 | Phase 1 |
| NCT02555644 | Eli Lilly and Company |
Head and Neck Neoplasms
|
February 24, 2016 | Phase 1 |
| NCT00091026 | National Cancer Institute (NCI) |
Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage II Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer
|
July 2004 | Phase 2 |
| NCT00148798 | Merck KGaA, Darmstadt, Germany |
Non Small Cell Lung Cancer (NSCLC)
|
October 2004 | Phase 3 |
| NCT05203172 | Pfizer |
Solid Tumors
|
July 5, 2022 | Phase 4 |
| NCT00646659 | European Organisation for Research and Treatment of Cancer - EORTC |
Head and Neck Cancer
|
February 2008 | Phase 2 |
| NCT00402545 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Bristol-Myers Squibb |
Head and Neck Neoplasms
|
January 2007 | Phase 1 |
| NCT00438737 | European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI) |
Colorectal Cancer|Metastatic Cancer
|
January 2007 | Phase 2 |
| NCT00923299 | Institut du Cancer de Montpellier - Val d´Aurelle |
Pancreatic Cancer
|
December 2008 | Phase 1|Phase 2 |
| NCT00815295 | Duke University|Bayer |
Squamous Cell Cancer
|
January 2008 | Phase 1|Phase 2 |
| NCT02268695 | Groupe Oncologie Radiotherapie Tete et Cou|Grupo Español de Tratamiento de Tumores de Cabeza y Cuello|AIO-Studien-gGmbH |
Head and Neck Squamous Cell Carcinoma
|
October 10, 2014 | Phase 2 |
| NCT00117962 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Eli Lilly and Company|Bristol-Myers Squibb |
Lung Cancer
|
September 2005 | Phase 2 |
| NCT00207051 | Bristol-Myers Squibb |
Colorectal Cancer
|
January 2006 | Phase 1 |
| NCT05104567 | Sanofi|Merck Sharp & Dohme LLC |
Oesophageal Squamous Cell Carcinoma|Gastric Cancer|Hepatocellular Carcinoma|Colorectal Cancer|Oseophageal Adenocarcinoma
|
December 9, 2021 | Phase 2 |
| NCT04670679 | Erasca, Inc. |
Advanced or Metastatic Solid Tumors
|
December 15, 2020 | Phase 1 |
| NCT00998101 | UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lung Cancer
|
July 2009 | Phase 2 |
| NCT00784667 | Austin Health|Ballarat Health Services|Queen Elizabeth Hospital, Adelaide|Royal North Shore Hospital |
Metastatic Colorectal Cancer
|
October 2008 | Phase 2 |
| NCT03881787 | Dragonboat Biopharmaceutical Company Limited|West China Hospital|Shanghai Public Health Clinical Center |
Healthy Volunteers
|
February 27, 2019 | Phase 1 |
| NCT04241731 | Jiangsu Cancer Institute & Hospital |
Colorectal Cancer
|
November 28, 2019 | Phase 2 |
| NCT04464967 | NKGen Biotech, Inc. |
Advanced Solid Tumor|Metastatic Cancer|HER2-positive Breast Cancer|HER2-positive Gastric Cancer|HER-2 Protein Overexpression|Esophageal Cancer|Ovarian Cancer|Endometrium Cancer|Bladder Cancer|Pancreatic Cancer|Colorectal Cancer|Non Small Cell Lung Cancer|EGF-R Positive Non-Small Cell Lung Cancer|Head and Neck Squamous Cell Carcinoma|Triple Negative Breast Cancer|Cervical Cancer|Sarcoma
|
March 2021 | Phase 1|Phase 2 |
| NCT03491709 | Dragonboat Biopharmaceutical Company Limited|Shanghai East Hospital |
Colorectal Cancer
|
July 1, 2018 | Phase 1 |
| NCT01326923 | Louisiana State University Health Sciences Center Shreveport |
Head and Neck Squamous Cell Cancer
|
June 2010 | Phase 2 |
| NCT01060423 | Hans-Joachim Schmoll, MD|Biocompatibles UK Ltd|Martin-Luther-Universität Halle-Wittenberg |
Colorectal Cancer
|
February 2010 | Phase 2 |
| NCT00600249 | Centre Jean Perrin|Merck Sharp & Dohme LLC|Sanofi |
Breast Cancer
|
January 2008 | Phase 2 |
| NCT00034541 | Eli Lilly and Company|University of Colorado, Denver|Greenwich Hospital|Indiana University |
Carcinoma, Non-Small-Cell Lung
|
December 2000 | Phase 1|Phase 2 |
| NCT00169247 | Groupe Oncologie Radiotherapie Tete et Cou|Tumor Study Group Head and Neck |
Larynx Cancer|Hypopharynx Cancer
|
October 2005 | Phase 2 |
| NCT01123811 | Johannes Gutenberg University Mainz|AIO-Studien-gGmbH |
Adenocarcinoma of Stomach or Esophagogastric Junction
|
May 2006 | Phase 2 |
| NCT02105636 | Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd |
Squamous Cell Carcinoma of the Head and Neck
|
May 29, 2014 | Phase 3 |
| NCT01009346 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Novartis Pharmaceuticals |
Head and Neck Cancer
|
October 2009 | Phase 1|Phase 2 |
| NCT03009058 | Immodulon Therapeutics Ltd |
Metastatic Cancer
|
May 24, 2017 | Phase 1|Phase 2 |
| NCT04776655 | Azienda Unità Sanitaria Locale Reggio Emilia|Istituto Di Ricerche Farmacologiche Mario Negri|Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale |
Colorectal Cancer|Metastatic Colorectal Cancer|RAS Mutation
|
April 30, 2021 | Phase 3 |
| NCT00665392 | GERCOR - Multidisciplinary Oncology Cooperative Group |
Head and Neck Cancer
|
February 2008 | Phase 2 |
| NCT01858662 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Grand Hôpital de Charleroi |
Metastatic Colorectal Cancer
|
January 2014 | Phase 2 |
| NCT05004350 | Pierre Fabre Medicament|Merck KGaA, Darmstadt, Germany |
BRAF V600E|Metastatic Colorectal Cancer
|
September 14, 2021 | Phase 2 |
| NCT03693170 | Pierre Fabre Medicament|Pfizer|Merck KGaA, Darmstadt, Germany|Ono Pharmaceutical Co. Ltd |
BRAF V600E-mutant Metastatic Colorectal Cancer
|
January 17, 2019 | Phase 2 |
| NCT03914170 | Institut du Cancer de Montpellier - Val d´Aurelle|Merck Serono International SA |
Colorectal Cancer
|
April 1, 2017 | |
| NCT01794845 | University of Miami |
Squamous Cell Carcinoma|Head and Neck Cancer|Recurrent Disease
|
June 3, 2013 | Phase 2 |
| NCT01075048 | Daiichi Sankyo, Inc. |
Metastatic Colorectal Cancer
|
January 26, 2010 | Phase 1|Phase 2 |
| NCT03290937 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Metastatic Colorectal Carcinoma|Stage IV Colorectal Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8
|
December 27, 2017 | Phase 1 |
| NCT01050426 | Royal Marsden NHS Foundation Trust|Merck Serono International SA |
Pancreatic Cancer
|
March 2009 | Phase 2 |
| NCT01216020 | Azienda USL 4 Prato|Università degli Studi di Brescia |
Head and Neck Neoplasms|Laryngeal Neoplasms|Mouth Neoplasms|Pharyngeal Neoplasms
|
October 2010 | Phase 2 |
| NCT01581970 | Masonic Cancer Center, University of Minnesota |
Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma
|
June 2012 | Phase 2 |
| NCT03422536 | University of Arizona|National Cancer Institute (NCI) |
Head and Neck Basaloid Carcinoma|Recurrent Head and Neck Squamous Cell Carcinoma|Recurrent Oropharyngeal Squamous Cell Carcinoma|Squamous Cell Carcinoma of Unknown Primary Origin|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma|Stage IV Oropharyngeal Squamous Cell Carcinoma|Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma|Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVA Nasopharyngeal Keratinizing Squamous Cell Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma|Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma|Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVB Nasopharyngeal Keratinizing Squamous Cell Carcinoma|Stage IVB Oropharyngeal Squamous Cell Carcinoma|Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma|Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVC Nasopharyngeal Keratinizing Squamous Cell Carcinoma|Stage IVC Oropharyngeal Squamous Cell Carcinoma|Head and Neck Cancer|Oropharyngeal Cancer|HNSCC|Stage IV Lip and Oral Cavity Squamous Cell Carcinoma
|
December 5, 2017 | Phase 2 |
| NCT04117945 | Academic and Community Cancer Research United|National Cancer Institute (NCI) |
BRAF V600E Negative|KRAS Gene Mutation Negative|Locally Advanced Unresectable Colorectal Adenocarcinoma|Metastatic Colorectal Adenocarcinoma|NRAS Gene Mutation Negative|Stage III Colorectal Cancer AJCC v8|Stage IIIA Colorectal Cancer AJCC v8|Stage IIIB Colorectal Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8
|
March 3, 2020 | Phase 2 |
| NCT00499369 | National Cancer Institute (NCI)|North Central Cancer Treatment Group|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|NCIC Clinical Trials Group |
Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer
|
June 2007 | Phase 3 |
| NCT00964457 | Copenhagen University Hospital at Herlev |
Rectum Cancer
|
August 2009 | Phase 2 |
| NCT05155124 | Wuhan Union Hospital, China |
Colorectal Neoplasms Malignant
|
September 2022 | Phase 1 |
| NCT01609231 | Merck Sharp & Dohme LLC |
Rectal Neoplasms
|
July 6, 2012 | Phase 2 |
| NCT00609284 | Groupe Oncologie Radiotherapie Tete et Cou |
HNSCC
|
February 15, 2008 | Phase 3 |
| NCT00122460 | Merck KGaA, Darmstadt, Germany |
Head and Neck Cancer
|
December 2004 | Phase 3 |
| NCT00462735 | Johnny Kao|Icahn School of Medicine at Mount Sinai |
Head and Neck Cancer|Cancer of the Pharynx|Cancer of the Larynx|Nose Neoplasms|Paranasal Sinus Neoplasms|Cancer of the Oral Cavity
|
February 2007 | Phase 2 |
| NCT05395052 | Fate Therapeutics |
Non Small Cell Lung Cancer|Colorectal Cancer|Breast Cancer|Ovarian Cancer|Pancreatic Cancer|Head and Neck Cancer|GastroEsophageal Cancer
|
May 31, 2022 | Phase 1 |
| NCT01012258 | Merck KGaA, Darmstadt, Germany |
Squamous Cell Carcinoma of the Head and Neck
|
February 2009 | Phase 3 |
| NCT01063075 | Eli Lilly and Company |
Solid Tumor
|
June 2010 | Phase 2 |
| NCT00448097 | The Methodist Hospital Research Institute|Bristol-Myers Squibb|Eli Lilly and Company |
Prostatic Neoplasms
|
February 2007 | Phase 2 |
| NCT00148109 | University of Michigan Rogel Cancer Center|Bristol-Myers Squibb|Eli Lilly and Company |
Sarcoma
|
June 2005 | Phase 2 |
| NCT00084773 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Colorectal Cancer
|
March 2004 | Not Applicable |
| NCT00265941 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology |
Head and Neck Cancer
|
November 2005 | Phase 3 |
| NCT02630420 | Yale University |
Colorectal Cancer
|
January 2017 | Phase 1 |
| NCT00063141 | Eli Lilly and Company|Bristol-Myers Squibb |
Colorectal Cancer
|
April 2003 | Phase 3 |
| NCT04349267 | Bristol-Myers Squibb |
Advanced Solid Tumor
|
July 14, 2020 | Phase 1|Phase 2 |
| NCT00594984 | Bristol-Myers Squibb |
Metastatic Colorectal Cancer (MCRC)
|
May 2008 | Phase 1|Phase 2 |
| NCT01317433 | Institut Cancerologie de l´Ouest |
Colorectal Cancer Metastatic|Skin Toxicity
|
December 29, 2010 | Not Applicable |
| NCT04282109 | Grupo Español de Tratamiento de Tumores de Cabeza y Cuello|Bristol-Myers Squibb|Apices Soluciones S.L. |
Recurrent Head and Neck Squamous Cell Carcinoma|Head and Neck Cancer Stage IV
|
June 3, 2020 | Phase 2 |
| NCT02278133 | Array BioPharma |
Metastatic Colorectal Cancer
|
December 2014 | Phase 1|Phase 2 |
| NCT04856631 | Shanghai Junshi Bioscience Co., Ltd. |
Head and Neck Squamous Cell Cancer
|
February 2, 2021 | Phase 1|Phase 2 |
| NCT04984369 | Shanghai Henlius Biotech |
CRC
|
August 11, 2021 | Phase 2 |
| NCT00755534 | Hellenic Oncology Research Group|University Hospital of Crete |
Colorectal Cancer
|
November 2008 | Phase 2 |
| NCT03608046 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
Colorectal Neoplasms, Malignant
|
October 3, 2018 | Phase 2 |
| NCT01787006 | University Hospital Schleswig-Holstein |
Esophageal Cancer
|
September 2011 | Phase 2 |
| NCT01637194 | Fox Chase Cancer Center|National Cancer Institute (NCI) |
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Colon Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Basal Cell Carcinoma of the Lip|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Lymphoepithelioma of the Oropharynx|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Stage IVA Colon Cancer|Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Colon Cancer|Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Tongue Cancer
|
November 2008 | Phase 1 |
| NCT01247337 | Dorte Nielsen|Herlev Hospital |
Cholangiocarcinoma
|
February 2, 2011 | Phase 2 |
| NCT00705016 | Merck KGaA, Darmstadt, Germany |
Squamous Cell Cancer
|
October 2008 | Phase 1|Phase 2 |
| NCT03785249 | Mirati Therapeutics Inc. |
Advanced Cancer|Metastatic Cancer|Malignant Neoplastic Disease
|
January 15, 2019 | Phase 1|Phase 2 |
| NCT01256385 | National Cancer Institute (NCI) |
Recurrent Hypopharyngeal Squamous Cell Carcinoma|Recurrent Laryngeal Squamous Cell Carcinoma|Recurrent Laryngeal Verrucous Carcinoma|Recurrent Lip and Oral Cavity Squamous Cell Carcinoma|Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary|Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma|Recurrent Oral Cavity Verrucous Carcinoma|Recurrent Oropharyngeal Squamous Cell Carcinoma|Recurrent Salivary Gland Carcinoma|Salivary Gland Squamous Cell Carcinoma|Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary|Stage IV Hypopharyngeal Squamous Cell Carcinoma|Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma|Stage IVA Laryngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Verrucous Carcinoma|Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma|Stage IVA Major Salivary Gland Carcinoma|Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVA Oral Cavity Verrucous Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma|Stage IVB Laryngeal Squamous Cell Carcinoma|Stage IVB Laryngeal Verrucous Carcinoma|Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma|Stage IVB Major Salivary Gland Carcinoma|Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVB Oral Cavity Verrucous Carcinoma|Stage IVB Oropharyngeal Squamous Cell Carcinoma|Stage IVC Laryngeal Squamous Cell Carcinoma|Stage IVC Laryngeal Verrucous Carcinoma|Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma|Stage IVC Major Salivary Gland Carcinoma|Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVC Oral Cavity Verrucous Carcinoma|Stage IVC Oropharyngeal Squamous Cell Carcinoma|Tongue Carcinoma
|
November 2010 | Phase 2 |
| NCT00852228 | Association pour la Recherche sur le Temps Biologique et la Chronothérapie|Gustave Roussy, Cancer Campus, Grand Paris|Merck Serono International SA|Pfizer|CRESGE |
Metastatic Colorectal Cancer|Liver Metastases|Hepatic Lesions
|
July 2008 | Phase 2 |
| NCT03647423 | ImmunityBio, Inc. |
Chordoma|Unresectable Malignant Neoplasm
|
August 31, 2018 | Phase 1|Phase 2 |
| NCT01703390 | Arbeitsgemeinschaft medikamentoese Tumortherapie|Merck Sharp & Dohme LLC |
Metastatic Colorectal Cancer
|
December 4, 2012 | Phase 2 |
| NCT00544349 | Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute (NCI) |
Colorectal Cancer|Metastatic Cancer
|
October 2006 | Phase 2 |
| NCT05260671 | Eye & ENT Hospital of Fudan University |
Head and Neck Neoplasms|Recurrent Disease|Metastatic Cancer
|
January 25, 2022 | Phase 2 |
| NCT04466254 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. |
Metastatic Colorectal Cancer
|
December 7, 2020 | Phase 2 |
| NCT00557102 | National Cancer Institute, France|University Hospital, Grenoble |
Colorectal Cancer|Metastatic Cancer
|
September 2007 | Phase 2 |
| NCT00397384 | National Cancer Institute (NCI) |
Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Advanced Adult Primary Liver Cancer|Carcinoma of the Appendix|Gastrointestinal Stromal Tumor|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Colon Cancer|Recurrent Esophageal Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Recurrent Gastric Cancer|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Pancreatic Cancer|Recurrent Rectal Cancer|Recurrent Salivary Gland Cancer|Recurrent Small Intestine Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Small Intestine Adenocarcinoma|Small Intestine Leiomyosarcoma|Small Intestine Lymphoma|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Anal Cancer|Stage IV Basal Cell Carcinoma of the Lip|Stage IV Colon Cancer|Stage IV Esophageal Cancer|Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IV Gastric Cancer|Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Lymphoepithelioma of the Oropharynx|Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Pancreatic Cancer|Stage IV Rectal Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Tongue Cancer|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer
|
January 2007 | Phase 1 |
| NCT04485013 | Tizona Therapeutics, Inc |
Cancer
|
July 14, 2020 | Phase 1 |
| NCT03524326 | Memorial Sloan Kettering Cancer Center |
Head and Neck Squamous Cell Carcinoma|Cutaneous Squamous Cell Carcinoma|Head and Neck Cancer|Head and Neck Carcinoma
|
April 30, 2018 | Phase 1 |
| NCT02953782 | Gilead Sciences|California Institute for Regenerative Medicine (CIRM) |
Solid Tumor|Colorectal Cancer
|
November 2, 2016 | Phase 1|Phase 2 |
| NCT01177956 | Merck KGaA, Darmstadt, Germany |
Squamous Cell Carcinoma of the Head and Neck
|
December 2009 | Phase 3 |
| NCT01086267 | Bristol-Myers Squibb |
Colorectal Cancer
|
July 2010 | Phase 1|Phase 2 |
| NCT00182715 | Velindre NHS Trust|National Cancer Institute (NCI) |
Colorectal Cancer
|
March 2005 | Phase 3 |
| NCT01126450 | Case Comprehensive Cancer Center |
Colon Cancer|Rectal Cancer
|
October 2009 | Phase 1 |
| NCT01280643 | Fox Chase Cancer Center|National Cancer Institute (NCI) |
Metastatic Colorectal Cancer
|
March 2010 | Not Applicable |
| NCT01044225 | Bart Neyns|Universitair Ziekenhuis Brussel |
Glioblastoma
|
September 2009 | Phase 2 |
| NCT00623558 | Seoul National University Hospital|Clinical Research Center for Solid Tumor, Korea |
Head and Neck Neoplasm
|
April 2008 | Phase 2 |
| NCT01718808 | Swiss Group for Clinical Cancer Research |
Metastatic Colorectal Cancer
|
November 2012 | Phase 2 |
| NCT00700440 | Sun Yat-sen University|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Sichuan Cancer Hospital and Research Institute|Fujian Cancer Hospital|Fudan University|Cancer Hospital of Guizhou Province|First Affiliated Hospital of Guangxi Medical University|Central South University |
Nasopharyngeal Carcinoma
|
July 2008 | Phase 2 |
| NCT00561054 | Grupo Portugues de Estudo do Cancro do Pulmao |
Carcinoma, Non-Small-Cell Lung
|
March 2007 | Phase 2 |
| NCT04956640 | Eli Lilly and Company|Loxo Oncology, Inc.|Merck Sharp & Dohme LLC |
Carcinoma, Non-Small-Cell Lung|Colorectal Neoplams|Endometrial Neoplasms|Ovarian Neoplasms|Pancreatic Neoplasms
|
July 19, 2021 | Phase 1 |
| NCT01867697 | Per Pfeiffer|Merck Serono International SA|Odense University Hospital |
Metastatic Colorectal Cancer
|
May 2012 | Phase 2 |
| NCT04229459 | Baruch Brenner|Bristol-Myers Squibb|Merck Serono International SA|Rabin Medical Center |
Esophageal Squamous Cell Carcinoma
|
December 30, 2019 | Phase 2 |
| NCT01081041 | Eli Lilly and Company |
Head and Neck Cancer
|
June 2010 | Phase 2 |
| NCT01082315 | Merck KGaA, Darmstadt, Germany |
Colorectal Neoplasms
|
April 2009 | |
| NCT02358031 | Merck Sharp & Dohme LLC |
Recurrent Head and Neck Cancer|Metastatic Head and Neck Cancer
|
March 19, 2015 | Phase 3 |
| NCT00466505 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) |
Colorectal Cancer
|
May 2005 | Phase 2 |
| NCT00851877 | University of Texas Southwestern Medical Center |
Head and Neck Cancer
|
March 1, 2009 | Phase 1|Phase 2 |
| NCT01218048 | Robert Ferris|Bristol-Myers Squibb|University of Pittsburgh |
Squamous Cell Carcinoma of the Head and Neck
|
February 2011 | Phase 2 |
| NCT00077233 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Bristol-Myers Squibb|Eli Lilly and Company |
Colorectal Cancer
|
December 2003 | Phase 3 |
| NCT00551213 | Merck Sharp & Dohme LLC |
Colorectal Cancer
|
November 21, 2007 | Phase 2 |
| NCT03186326 | Federation Francophone de Cancerologie Digestive |
Metastatic Colorectal Cancer|MSI
|
April 24, 2018 | Phase 2 |
| NCT00251381 | Trial Form Support S.L.|Merck KGaA, Darmstadt, Germany |
Oropharyngeal Neoplasms
|
November 2005 | Phase 2 |
| NCT04359199 | Loren Mell, MD|University of California, San Diego |
Head and Neck Cancer|Dysphagia|Oropharyngeal Dysphagia|Oropharynx Cancer|Oropharynx Squamous Cell Carcinoma
|
September 1, 2020 | |
| NCT00118183 | National Cancer Institute (NCI) |
Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Large Cell Lung Cancer|Malignant Pleural Effusion|Recurrent Non-small Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer
|
July 2005 | Phase 2 |
| NCT02484833 | Armando Orlandi|Catholic University of the Sacred Heart |
Antineoplastic Agents
|
February 2015 | Phase 3 |
| NCT05504278 | Innovent Biologics (Suzhou) Co. Ltd. |
Advanced Non-Small Cell Lung Cancer
|
August 31, 2022 | Phase 1 |
| NCT00828841 | Accelerated Community Oncology Research Network |
Non-Small Cell Lung Cancer
|
December 2008 | Phase 2 |
| NCT01075828 | Merck KGaA, Darmstadt, Germany |
Head and Neck Cancer
|
March 2009 | |
| NCT00477880 | Vanderbilt University|National Cancer Institute (NCI)|Vanderbilt University Medical Center |
Gastric Cancer|Precancerous Condition
|
April 2001 | Phase 1 |
| NCT00540943 | GlaxoSmithKline |
Neoplasms, Colorectal
|
July 13, 2007 | Phase 1 |
| NCT01326559 | Hong Kong Nasopharyngeal Cancer Study Group Limited|The University of Hong Kong|Sanofi|Merck Sharp & Dohme LLC|Roche Pharma AG |
Nasopharyngeal Carcinoma
|
June 2010 | Phase 2 |
| NCT01472653 | Institute of Oncology Ljubljana |
Head and Neck Cancer
|
December 2011 | Phase 2 |
| NCT00986674 | National Cancer Institute (NCI) |
Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer
|
September 2009 | Phase 2 |
| NCT01427205 | M.D. Anderson Cancer Center|OSI Pharmaceuticals |
Head and Neck Cancer
|
June 2013 | Phase 2 |
| NCT00003809 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Head and Neck Cancer
|
June 1999 | Phase 3 |
| NCT00755118 | University Hospital of Crete |
Colorectal Cancer
|
October 2008 | Phase 2 |
| NCT00955240 | UNICANCER |
Anal Cancer
|
March 2009 | Phase 2 |
| NCT01283334 | Emory University|Novartis |
Head and Neck Neoplasms|Cancer of the Head and Neck
|
January 2011 | Phase 1|Phase 2 |
| NCT00517829 | US Oncology Research|Eli Lilly and Company|Sanofi |
Gastric Cancer Adenocarcinoma Metastatic
|
July 2007 | Phase 2 |
| NCT00368121 | Prof. Dr. Andreas Engert|The Clinical Trials Centre Cologne|University of Cologne |
Multiple Myeloma
|
August 2006 | Phase 2 |
| NCT00305877 | National Cancer Institute (NCI) |
Stage IA Pancreatic Cancer|Stage IB Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer
|
February 2006 | Phase 2 |
| NCT00095199 | Eli Lilly and Company |
Non Small Cell Lung Cancer
|
January 2005 | Phase 3 |
| NCT00985855 | Institut de Cancérologie de la Loire |
Non-Small-Cell Lung Carcinoma
|
September 2009 | Phase 2 |
| NCT00291707 | University of Pittsburgh|Eli Lilly and Company|Bristol-Myers Squibb |
Head and Neck Cancer
|
March 2006 | Phase 1 |
| NCT00640081 | Cheryl Pugh|Medical Research Council |
Colorectal Cancer
|
July 2007 | Phase 2 |
| NCT00165490 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital |
Adenocarcinoma of Esophagus|Squamous Cell Carcinoma of Esophagus
|
August 2004 | Phase 2 |
| NCT00768131 | Eli Lilly and Company |
Lung Neoplasms|Carcinoma, Non-Small-Cell Lung
|
October 2008 | Phase 2 |
| NCT02270814 | Washington University School of Medicine|Celgene Corporation |
Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma|Cancer of the Head and Neck
|
February 2, 2015 | Phase 2 |
| NCT05355701 | Pfizer |
Melanoma|Colorectal Cancer|Non-Small-Cell Lung Cancer|Thyroid Cancer|Glioma
|
July 5, 2022 | Phase 1 |
| NCT00005591 | University of Alabama at Birmingham|National Cancer Institute (NCI) |
Pancreatic Cancer
|
October 1999 | Phase 2 |
| NCT00311857 | Heidelberg University|Merck KGaA, Darmstadt, Germany |
Glioblastoma Multiforme
|
February 2006 | Phase 1|Phase 2 |
| NCT01001377 | Amgen |
Metastatic Colorectal Cancer
|
February 2, 2010 | Phase 3 |
| NCT04722523 | Memorial Sloan Kettering Cancer Center|Regeneron Pharmaceuticals |
Head and Neck Cancer|Head Cancer|Head Cancer Neck|Neck Cancer|Head and Neck Squamous Cell Carcinoma|HNSCC
|
January 20, 2021 | Phase 1 |
| NCT01442649 | UNICANCER |
Colorectal Cancer
|
December 2010 | Phase 2 |
| NCT00904345 | University of Michigan Rogel Cancer Center |
Head and Neck Cancer
|
April 2009 | Phase 2 |
| NCT00265811 | Federation Francophone de Cancerologie Digestive |
Colorectal Cancer
|
November 2005 | Phase 3 |
| NCT03688230 | SFJ Pharmaceuticals X, LTD.|SFJ Pharmaceuticals, Inc.|Merck KGaA, Darmstadt, Germany|AIO-Studien-gGmbH|Academic and Community Cancer Research United |
Metastatic Colorectal Cancer
|
April 2019 | Phase 2 |
| NCT04616183 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Metastatic Colon Adenocarcinoma|Metastatic Colorectal Carcinoma|Metastatic Rectal Adenocarcinoma|Recurrent Colorectal Carcinoma|Stage III Colon Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8|Stage III Rectal Cancer AJCC v8|Stage IIIA Colon Cancer AJCC v8|Stage IIIA Colorectal Cancer AJCC v8|Stage IIIA Rectal Cancer AJCC v8|Stage IIIB Colon Cancer AJCC v8|Stage IIIB Colorectal Cancer AJCC v8|Stage IIIB Rectal Cancer AJCC v8|Stage IIIC Colon Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IIIC Rectal Cancer AJCC v8|Stage IV Colon Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Rectal Cancer AJCC v8|Stage IVA Colon Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVA Rectal Cancer AJCC v8|Stage IVB Colon Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVB Rectal Cancer AJCC v8|Stage IVC Colon Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8|Stage IVC Rectal Cancer AJCC v8|Unresectable Colon Adenocarcinoma|Unresectable Colorectal Carcinoma|Unresectable Rectal Adenocarcinoma
|
December 2, 2020 | Phase 1|Phase 2 |
| NCT03254927 | Celldex Therapeutics |
Advanced Head and Neck Squamous Cell Carcinoma
|
March 27, 2018 | Phase 2 |
| NCT00207116 | Eli Lilly and Company |
Carcinoma, Non-Small-Cell Lung|Neoplasm Metastasis
|
September 2005 | Phase 1 |
| NCT00865098 | Merck KGaA, Darmstadt, Germany |
Carcinoma of the Head and Neck
|
March 2009 | Phase 2 |
| NCT00353717 | Hadassah Medical Organization |
Breast Neoplasms
|
November 2006 | Phase 1|Phase 2 |
| NCT05497336 | Innovent Biologics (Suzhou) Co. Ltd. |
Colorectal Cancer
|
August 18, 2022 | Phase 1 |
| NCT00020917 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Colorectal Cancer
|
February 2001 | Phase 2 |
| NCT01097642 | The Methodist Hospital Research Institute|Bristol-Myers Squibb |
Breast Cancer
|
October 10, 2008 | Phase 2 |
| NCT01919879 | UNICANCER |
Metastatic Colorectal Cancer
|
October 2012 | Phase 2 |
| NCT01057589 | Eli Lilly and Company |
Head and Neck Neoplasms
|
February 2010 | Phase 2 |
| NCT00927147 | Boneca Corporation |
Head and Neck Cancer
|
June 2009 | Phase 1|Phase 2 |
| NCT00271011 | University of Michigan Rogel Cancer Center |
Colorectal Cancer
|
December 2005 | Phase 2 |
| NCT01621217 | Lund University Hospital|Merck Sharp & Dohme LLC |
Locally Advanced Cancer in the Anal Region
|
June 2012 | Phase 1 |
| NCT03389477 | Washington University School of Medicine|Pfizer |
Head and Neck Squamous Cell Carcinoma
|
April 27, 2018 | Phase 2 |
| NCT02978313 | Ruijin Hospital|Jiangsu Cancer Institute & Hospital|Henan Cancer Hospital|Second Affiliated Hospital, School of Medicine, Zhejiang University |
Colorectal Cancer
|
November 2016 | Phase 2|Phase 3 |
| NCT00422773 | Technische Universität Dresden |
Metastatic Colorectal Cancer
|
January 2007 | Phase 1|Phase 2 |
| NCT03727724 | The Netherlands Cancer Institute|Boehringer Ingelheim|Merck Serono International SA |
Carcinoma, Non-Small-Cell Lung
|
December 4, 2018 | Phase 2 |
| NCT01008475 | Merck KGaA, Darmstadt, Germany |
Metastatic Colorectal Cancer
|
October 2009 | Phase 1|Phase 2 |
| NCT01216345 | Association of Research on the Biology of Liver Tumors |
Unresectable|Locally Advanced|Metastatic
|
October 2006 | Phase 2 |
| NCT04853043 | University of Utah |
Colorectal Cancer
|
November 3, 2021 | Phase 2 |
| NCT00941499 | M.D. Anderson Cancer Center |
Advanced Cancers
|
July 2009 | Phase 1 |
| NCT01303237 | Merck KGaA, Darmstadt, Germany|Merck Ltd., India |
Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck|LA SCCHN
|
February 28, 2011 | |
| NCT02143622 | Novartis Pharmaceuticals|Novartis |
Head and Neck Squamous Cell Carcinoma
|
March 2015 | Phase 1|Phase 2 |
| NCT00381706 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Bristol-Myers Squibb|Sanofi|Pfizer |
Esophageal Cancer
|
September 15, 2006 | Phase 2 |
| NCT00757549 | Mayo Clinic|National Cancer Institute (NCI) |
Head and Neck Cancer
|
September 2008 | Early Phase 1 |
| NCT01716416 | Washington University School of Medicine|Novartis Pharmaceuticals |
Squamous Cell Carcinoma of the Head and Neck
|
May 31, 2013 | Phase 1 |
| NCT00577109 | Hoffmann-La Roche|Merck KGaA, Darmstadt, Germany |
Colorectal Cancer
|
December 2007 | Phase 2 |
| NCT00497497 | Genentech, Inc. |
Colorectal Cancer
|
October 2007 | Phase 1 |
| NCT02934529 | Ludwig-Maximilians - University of Munich |
Metastatic Colorectal Cancer
|
March 2015 | Phase 3 |
| NCT00514943 | Boehringer Ingelheim |
Head and Neck Neoplasms|Carcinoma, Squamous Cell
|
August 2007 | Phase 2 |
| NCT00552149 | Gustave Roussy, Cancer Campus, Grand Paris|Merck Serono International SA |
Advanced Biliary Cancer
|
October 2007 | Phase 2 |
| NCT01266187 | RWTH Aachen University |
Liver Metastasis
|
July 2011 | Not Applicable |
| NCT03446157 | UNC Lineberger Comprehensive Cancer Center|Amgen|Pfizer |
Cancer of the Colon|Colon Cancer|Colon Neoplasms|Colonic Cancer|Neoplasms, Colonic
|
March 13, 2018 | Phase 2 |
| NCT00820755 | Merck KGaA, Darmstadt, Germany |
Non-Small Cell Lung Cancer (NSCLC)
|
January 2009 | Phase 3 |
| NCT01472016 | AbbVie (prior sponsor, Abbott)|AbbVie |
Advanced Solid Tumors
|
October 6, 2011 | Phase 1 |
| NCT04616196 | Nektar Therapeutics |
Head and Neck Squamous Cell Carcinoma|Colorectal Cancer|Cutaneous Squamous Cell Carcinoma|Anal Squamous Cell Carcinoma|Cervical Cancer
|
October 30, 2020 | Phase 1|Phase 2 |
| NCT00084318 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology |
Head and Neck Cancer
|
April 2004 | Phase 2 |
| NCT00678535 | Merck KGaA, Darmstadt, Germany |
Gastric Cancer
|
June 2008 | Phase 3 |
| NCT03169764 | ImmunityBio, Inc. |
Head and Neck Squamous Cell Carcinoma
|
December 2017 | Phase 1|Phase 2 |
| NCT02573220 | University of Chicago|National Cancer Institute (NCI) |
Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer
|
June 2015 | Phase 1 |
| NCT00999700 | Gruppo Oncologico del Nord-Ovest |
Squamous Cell Carcinoma of the Head and Neck
|
September 2009 | Phase 3 |
| NCT00671372 | Genentech, Inc. |
Colorectal Cancer
|
July 2006 | Phase 1 |
| NCT00252564 | US Oncology Research|Bristol-Myers Squibb|Memorial Sloan Kettering Cancer Center|Prologue Research International |
Metastatic Colorectal Cancer
|
September 2005 | Phase 3 |
| NCT00324415 | AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC |
Anal Cancer
|
September 2006 | Phase 2 |
| NCT00134069 | National Cancer Institute (NCI) |
Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage III Colon Cancer|Stage III Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer
|
June 2005 | Phase 1 |
| NCT00444678 | NYU Langone Health|Eli Lilly and Company|Bristol-Myers Squibb |
Colorectal Cancer|Neoplasm Metastasis
|
June 1, 2004 | Phase 2 |
| NCT00350025 | Fox Chase Cancer Center|Bristol-Myers Squibb |
Urologic Neoplasm
|
August 2006 | Phase 2 |
| NCT01412229 | UNC Lineberger Comprehensive Cancer Center|Celgene Corporation |
Head and Neck Cancer
|
February 2012 | Phase 2 |
| NCT00251186 | University of Medicine and Dentistry of New Jersey|Rutgers Cancer Institute of New Jersey|Bristol-Myers Squibb|Rutgers, The State University of New Jersey |
Colorectal Cancer
|
April 2006 | Phase 2 |
| NCT01973868 | Bayer |
Neoplasms
|
November 21, 2013 | Phase 1 |
| NCT02124850 | Celgene |
Squamous Cell Carcinoma of the Head and Neck
|
October 28, 2014 | Phase 1 |
| NCT01104922 | David A. Clump, MD, PhD|University of Pittsburgh |
Squamous Cell Carcinoma of the Head and Neck
|
December 26, 2007 | Phase 2 |
| NCT00522665 | Hoosier Cancer Research Network|Novartis Pharmaceuticals|Pfizer |
Colorectal Cancer
|
August 2007 | Phase 1|Phase 2 |
| NCT00815308 | Shandong Cancer Hospital and Institute|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Peking University Cancer Hospital & Institute|Hebei Fourth Hospital|Jiangsu Cancer Institute & Hospital|RenJi Hospital|The Affiliated Cancer Hospital of Zhengzhou University|West China Hospital |
Esophageal Cancer
|
January 2009 | Phase 2 |
| NCT04832776 | Fudan University |
Liver Metastasis Colon Cancer
|
April 17, 2021 | Phase 2 |
| NCT03944941 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Skin Squamous Cell Carcinoma|Metastatic Skin Cancer
|
May 17, 2019 | Phase 2 |
| NCT00315185 | Fox Chase Cancer Center |
Carcinoma, Non-Small-Cell Lung
|
December 2004 | Phase 2 |
| NCT00124618 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lung Cancer
|
January 2006 | Phase 2 |
| NCT01167725 | Walter Reed Army Medical Center|National Cancer Institute (NCI) |
Colorectal Cancer
|
August 2010 | Phase 3 |
| NCT04428151 | Merck Sharp & Dohme LLC|Eisai Inc. |
Squamous Cell Carcinoma of Head and Neck
|
August 6, 2020 | Phase 2 |
| NCT04106362 | Jonsson Comprehensive Cancer Center|Eli Lilly and Company |
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|KRAS Protein Variant|Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
|
January 14, 2020 | Phase 2 |
| NCT01935921 | National Cancer Institute (NCI) |
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
|
April 9, 2013 | Phase 1 |
| NCT00972881 | University College, London |
Rectal Cancer
|
April 2009 | Phase 1|Phase 2 |
| NCT00395252 | Carmen Schade-Brittinger|Philipps University Marburg Medical Center |
Adenocarcinoma
|
October 2006 | Phase 2 |
| NCT02236936 | Arbeitsgemeinschaft medikamentoese Tumortherapie|Medical University of Graz |
Squamous Cell Carcinoma of the Hypopharynx Stage III|Squamous Cell Carcinoma of the Hypopharynx Stage IV|Laryngeal Squamous Cell Carcinoma Stage III|Laryngeal Squamous Cell Carcinoma Stage IV|Oropharyngeal Squamous Cell Carcinoma Stage III|Oropharyngeal Squamous Cell Carcinoma Stage IV|Squamous Cell Carcinoma of the Oral Cavity Stage III|Squamous Cell Carcinoma of the Oral Cavity Stage IV|Locally Advanced Malignant Neoplasm
|
February 3, 2017 | Phase 3 |
| NCT00383695 | Royal Marsden NHS Foundation Trust |
Colorectal Cancer
|
September 2005 | Phase 2 |
| NCT04091867 | University of Colorado, Denver|Vasgene Therapeutics, Inc |
Squamous Cell Carcinoma of Head and Neck
|
January 6, 2020 | Phase 1 |
| NCT02627274 | Hoffmann-La Roche |
Solid Tumor|Breast Cancer|Cancer of Head and Neck
|
December 7, 2015 | Phase 1 |
| NCT00153998 | Technische Universität Dresden |
Colorectal Cancer|Liver Metastases
|
November 2004 | Phase 2 |
| NCT00681876 | Hellenic Oncology Research Group|University Hospital of Crete |
Colorectal Cancer
|
April 2008 | Phase 2 |
| NCT00326495 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic Colorectal Cancer
|
May 10, 2006 | Phase 2 |
| NCT01719380 | Pfizer |
Colorectal Cancer
|
November 23, 2012 | Phase 2 |
| NCT00811993 | Hoffmann-La Roche |
Neoplasms
|
February 2009 | Phase 1 |
| NCT01211938 | Gustave Roussy, Cancer Campus, Grand Paris|Ministry of Health, France |
Squamous Cell Carcinoma
|
June 15, 2010 | Phase 2|Phase 3 |
| NCT00997009 | National Cancer Institute, Naples |
Cervical Cancer
|
October 2009 | Phase 2 |
| NCT02942706 | Ruijin Hospital|Chinese PLA General Hospital|Xiangya Hospital of Central South University|West China Hospital|Tongji Hospital |
Colorectal Cancer
|
November 2021 | Phase 2|Phase 3 |
| NCT00882583 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb |
Head and Neck Cancer
|
July 2009 | Phase 1 |
| NCT02438995 | Northwell Health |
Carcinoma, Squamous Cell|Carcinoma, Squamous Cell of Head and Neck
|
May 2015 | Phase 1 |
| NCT00096174 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Head and Neck Cancer
|
December 2004 | Phase 2 |
| NCT00996567 | University Hospital, Ghent|Merck Sharp & Dohme LLC |
Cancer
|
October 2009 | Phase 2 |
| NCT00980239 | M.D. Anderson Cancer Center |
Liver Cancer|Advanced Cancer
|
September 2009 | Phase 1 |
| NCT00305760 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Pancreatic Cancer
|
December 2005 | Phase 2 |
| NCT00063401 | Eli Lilly and Company|Bristol-Myers Squibb |
Ovarian Cancer|Peritoneal Neoplasms|Fallopian Tube Neoplasms
|
September 2003 | Phase 2 |
| NCT00044863 | Eli Lilly and Company |
Colorectal Neoplasms|Metastases, Neoplasm
|
August 2002 | Phase 2 |
| NCT00409565 | National Cancer Institute (NCI) |
Head and Neck Cancer|Squamous Cell Carcinoma
|
September 2006 | Phase 2 |
| NCT01255800 | University of Colorado, Denver |
Recurrent Head and Neck Cancer
|
April 2011 | Phase 1 |
| NCT00251498 | Veeda Oncology|Bristol-Myers Squibb |
Carcinoma, Non-Small-Cell Lung
|
Phase 2 | |
| NCT00827671 | P.O. Witteveen|Merck KGaA, Darmstadt, Germany|UMC Utrecht |
Resectable Esophageal Cancer
|
March 2009 | Phase 2 |
| NCT01522612 | European Organisation for Research and Treatment of Cancer - EORTC|Merck KGaA, Darmstadt, Germany |
Colorectal Cancer Metastatic
|
April 2013 | Phase 2 |
| NCT00376727 | University of California, Davis|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
December 2004 | Phase 1 |
| NCT00207155 | Eli Lilly and Company |
Metastatic Colorectal Cancer
|
December 2003 | Phase 1 |
| NCT00430027 | University of Colorado, Denver|Bristol-Myers Squibb|Sanofi |
Esophageal Adenocarcinoma
|
November 2006 | Not Applicable |
| NCT00463073 | Rigshospitalet, Denmark|Aalborg University Hospital|Odense University Hospital |
Malignant Gliomas
|
August 2006 | Phase 2 |
| NCT05226871 | Pfizer |
Breast Cancer|Head and Neck Cancer
|
July 7, 2022 | Phase 2 |
| NCT00719199 | EMD Serono |
Colorectal Cancer
|
January 2009 | Phase 1 |
| NCT00433927 | PD Dr. med. Volker Heinemann|Merck KGaA, Darmstadt, Germany|Ludwig-Maximilians - University of Munich |
Neoplasm Metastasis|Colorectal Cancer
|
January 2007 | Phase 3 |
| NCT03717155 | Merck KGaA, Darmstadt, Germany |
Squamous Non-Small Cell Lung Cancer
|
October 30, 2018 | Phase 2 |
| NCT00580073 | University of Wisconsin, Madison|Sanofi|Bristol-Myers Squibb|Eli Lilly and Company |
Rectal Cancer
|
December 2007 | Phase 2 |
| NCT03031444 | Peking University Cancer Hospital & Institute|Beijing Municipal Administration of Hospitals|West China Hospital|Zhejiang Cancer Hospital|The First Affiliated Hospital of Kunming Medical College |
Colorectal Cancer Stage IV|Metastasis
|
January 2016 | Phase 2|Phase 3 |
| NCT02938273 | The Netherlands Cancer Institute|Merck KGaA, Darmstadt, Germany |
Carcinoma, Squamous Cell of Head and Neck
|
February 1, 2017 | Phase 1 |
| NCT00216203 | Nasser Hanna, M.D.|Eli Lilly and Company|Bristol-Myers Squibb|Walther Cancer Institute|Hoosier Cancer Research Network |
Non-Small Cell Lung Cancer
|
May 2005 | Phase 1|Phase 2 |
| NCT00097214 | Eli Lilly and Company|Bristol-Myers Squibb |
Non-small Cell Lung Cancer
|
November 2004 | Phase 2 |
| NCT00110357 | Eli Lilly and Company |
Cancer|Refractory Solid Tumor
|
August 2005 | Phase 1 |
| NCT00392769 | M.D. Anderson Cancer Center|Bristol-Myers Squibb |
Endometrial Cancer
|
October 2006 | Phase 2 |
| NCT02071069 | Tianshu Liu|Shanghai Zhongshan Hospital |
Incurable Colorectal Cancer|RAS-wild-type
|
July 2013 | Phase 2 |
| NCT05063552 | National Cancer Institute (NCI) |
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Metastatic Head and Neck Squamous Cell Carcinoma|Metastatic Hypopharyngeal Squamous Cell Carcinoma|Metastatic Laryngeal Squamous Cell Carcinoma|Metastatic Lip and Oral Cavity Carcinoma|Metastatic Nasal Cavity Squamous Cell Carcinoma|Metastatic Nasopharyngeal Squamous Cell Carcinoma|Metastatic Pharyngeal Squamous Cell Carcinoma|Metastatic Sinonasal Squamous Cell Carcinoma|Recurrent Head and Neck Squamous Cell Carcinoma|Recurrent Hypopharyngeal Squamous Cell Carcinoma|Recurrent Laryngeal Squamous Cell Carcinoma|Recurrent Lip and Oral Cavity Squamous Cell Carcinoma|Recurrent Nasopharyngeal Squamous Cell Carcinoma|Recurrent Pharyngeal Squamous Cell Carcinoma|Recurrent Sinonasal Squamous Cell Carcinoma|Stage IV Hypopharyngeal Carcinoma AJCC v8|Stage IV Laryngeal Cancer AJCC v8|Stage IV Lip and Oral Cavity Cancer AJCC v8|Stage IV Nasopharyngeal Carcinoma AJCC v8|Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8|Stage IV Sinonasal Cancer AJCC v8
|
December 16, 2021 | Phase 2|Phase 3 |
| NCT00551759 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Esophageal Cancer
|
June 2008 | Phase 2 |
| NCT01031212 | University of California, San Francisco|Novartis Pharmaceuticals |
Tumors
|
January 2010 | Phase 1 |
| NCT01727869 | Regeneron Pharmaceuticals |
Cancer
|
October 2012 | Phase 1 |
| NCT00398398 | Asan Medical Center |
Gastric Cancer
|
November 2006 | Phase 2 |
| NCT02020577 | Boehringer Ingelheim |
Neoplasms
|
December 2013 | Phase 1 |
| NCT04673955 | Pierre Fabre Pharma GmbH|iOMEDICO AG|Pierre Fabre Pharma AG|Pierre Fabre Pharma Austria |
Metastatic Colorectal Carcinoma
|
September 3, 2020 | |
| NCT00527111 | US Oncology Research|Bristol-Myers Squibb|Eli Lilly and Company |
Rectal Cancer
|
February 2007 | Phase 2 |
| NCT01382407 | Rambam Health Care Campus|Merck KGaA, Darmstadt, Germany |
Colorectal Cancer Metastatic
|
July 2011 | |
| NCT00694603 | Lecia V. Sequist|Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Beth Israel Deaconess Medical Center|Unity Health Toronto|Bristol-Myers Squibb|Massachusetts General Hospital |
Non-small Cell Lung Cancer
|
September 2006 | Phase 2 |
| NCT01254617 | National Cancer Institute (NCI) |
Recurrent Colon Carcinoma|Recurrent Hypopharyngeal Squamous Cell Carcinoma|Recurrent Laryngeal Squamous Cell Carcinoma|Recurrent Laryngeal Verrucous Carcinoma|Recurrent Lip and Oral Cavity Squamous Cell Carcinoma|Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary|Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma|Recurrent Oral Cavity Verrucous Carcinoma|Recurrent Oropharyngeal Squamous Cell Carcinoma|Recurrent Rectal Carcinoma|Recurrent Salivary Gland Carcinoma|Salivary Gland Squamous Cell Carcinoma|Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary|Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7|Stage IVA Colon Cancer AJCC v7|Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Laryngeal Verrucous Carcinoma AJCC v7|Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVA Major Salivary Gland Cancer AJCC v7|Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7|Stage IVA Oral Cavity Cancer AJCC v6 and v7|Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Rectal Cancer AJCC v7|Stage IVB Colon Cancer AJCC v7|Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Laryngeal Verrucous Carcinoma AJCC v7|Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVB Major Salivary Gland Cancer AJCC v7|Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7|Stage IVB Oral Cavity Cancer AJCC v6 and v7|Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Rectal Cancer AJCC v7|Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVC Laryngeal Verrucous Carcinoma AJCC v7|Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVC Major Salivary Gland Cancer AJCC v7|Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7|Stage IVC Oral Cavity Cancer AJCC v6 and v7|Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7|Tongue Carcinoma
|
February 10, 2011 | Phase 1 |
| NCT00042939 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Pancreatic Cancer
|
July 2003 | Phase 2 |
| NCT00524017 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Head and Neck Cancer|Precancerous Condition
|
May 2007 | Phase 2 |
| NCT00193219 | SCRI Development Innovations, LLC|Bristol-Myers Squibb |
Colon Cancer
|
July 2005 | Phase 2 |
| NCT02298595 | Julie E. Bauman, MD, MPH|Novartis|University of Pittsburgh |
Carcinoma, Squamous|Squamous Cell Carcinoma|Oropharyngeal Neoplasms|Oropharyngeal Cancer
|
August 2016 | Phase 1|Phase 2 |
| NCT00954512 | Merck Sharp & Dohme LLC |
Neoplasms
|
September 25, 2009 | Phase 1|Phase 2 |
| NCT01099358 | Eli Lilly and Company |
Solid Tumor
|
April 2010 | Phase 2 |
| NCT00661492 | US Oncology Research|Eli Lilly and Company|Oregon Health and Science University |
Androgen-independent Prostate Cancer
|
May 2008 | Phase 2 |
| NCT01326000 | Hoffmann-La Roche |
Colorectal Cancer
|
April 2011 | Phase 2 |
| NCT03524820 | Hadassah Medical Organization|Merck Serono International SA |
Cancer of Colon
|
October 17, 2017 | Phase 2 |
| NCT01979211 | University of Cincinnati |
Head and Neck Cancer
|
October 2013 | Phase 2 |
| NCT00056030 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Colorectal Cancer|Metastatic Cancer
|
December 2004 | Phase 2 |
| NCT00891904 | Roswell Park Cancer Institute |
Head and Neck Cancer
|
April 2009 | Not Applicable |
| NCT01816984 | University of Chicago|National Cancer Institute (NCI) |
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Tongue Cancer
|
May 2013 | Phase 1|Phase 2 |
| NCT02822482 | UNICANCER |
Carcinoma, Squamous Cell of Head and Neck
|
June 2016 | Phase 1|Phase 2 |
| NCT01884623 | Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute, France|Ligue contre le cancer, France|Merck Serono International SA |
Head Neck Cancer Squamous Cell Recurrent
|
November 6, 2013 | Phase 3 |
| NCT02117466 | Amsterdam UMC, location VUmc|University Medical Center Groningen|Radboud University Medical Center |
Metastatic Colorectal Cancer
|
April 2014 | Phase 1|Phase 2 |
| NCT03563157 | ImmunityBio, Inc. |
Colorectal Cancer Metastatic|mCRC
|
May 25, 2018 | Phase 1|Phase 2 |
| NCT03563170 | ImmunityBio, Inc. |
Hepatocellular Carcinoma Non-resectable|Hepatocellular Carcinoma Recurrent
|
May 25, 2018 | Phase 1|Phase 2 |
| NCT00079274 | National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Adenocarcinoma of the Colon|Stage III Colon Cancer
|
February 2004 | Phase 3 |
| NCT02324608 | Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey |
Recurrent Skin Cancer|Squamous Cell Carcinoma of the Skin
|
January 30, 2015 | Not Applicable |
| NCT00142428 | Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women´s Hospital|Bristol-Myers Squibb |
Hepatocellular Carcinoma
|
January 2005 | Phase 2 |
| NCT01855451 | Trans Tasman Radiation Oncology Group |
HPV Positive Oropharyngeal Squamous Cell Carcinoma
|
June 3, 2013 | Phase 3 |
| NCT00803647 | NSABP Foundation Inc|Bristol-Myers Squibb |
Metastatic Colorectal Cancer
|
January 2010 | Phase 2 |
| NCT01190462 | Leiden University Medical Center|National Cancer Institute (NCI) |
Colorectal Cancer
|
August 2010 | Phase 2 |
| NCT01294826 | Swedish Medical Center|Novartis Pharmaceuticals |
Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer|Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum
|
February 2011 | Phase 1 |
| NCT01074333 | Merck KGaA, Darmstadt, Germany|Merck Ltd. |
Colorectal Neoplasm
|
September 2008 | |
| NCT01059188 | Swiss Group for Clinical Cancer Research |
Lung Cancer
|
May 3, 2010 | Phase 2 |
| NCT04800822 | Pfizer |
Solid Tumor
|
March 17, 2021 | Phase 1 |
| NCT03386838 | Bristol-Myers Squibb |
Head and Neck Cancer
|
March 28, 2018 | Phase 3 |
| NCT00765011 | Grupo Español de Tratamiento de Tumores de Cabeza y Cuello |
Head and Neck Cancer
|
October 2008 | Phase 2 |
| NCT00934518 | Milton S. Hershey Medical Center |
Squamous Cell Cancer of the Head and Neck
|
July 2009 | Phase 2 |
| NCT00971932 | Merck KGaA, Darmstadt, Germany |
Squamous Cell Carcinoma of the Head and Neck
|
July 2009 | Phase 2 |
| NCT00640471 | NCIC Clinical Trials Group|Canadian Cancer Trials Group |
Colorectal Cancer
|
February 5, 2008 | Phase 3 |
| NCT03666325 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Merck Sharp & Dohme LLC |
Skin Neoplasm
|
October 1, 2018 | Phase 2 |
| NCT01467115 | Drexel University College of Medicine|Drexel University |
Head and Neck Cancer
|
March 2010 | Phase 2 |
| NCT02994888 | Royal Marsden NHS Foundation Trust |
Metastatic Colorectal Cancer
|
November 2012 | |
| NCT00636298 | Emory University|Genentech, Inc. |
Esophageal Carcinoma
|
October 2008 | Phase 2 |
| NCT00716456 | Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb |
Lung Adenocarcinoma
|
July 2008 | Phase 1|Phase 2 |
| NCT01776307 | Sumitomo Pharma Oncology, Inc. |
Colorectal Cancer
|
March 2012 | Phase 2 |
| NCT03169777 | ImmunityBio, Inc. |
Colorectal Cancer
|
August 2018 | Phase 1|Phase 2 |
| NCT00629226 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Head and Neck Cancer
|
October 2007 | Phase 1 |
| NCT00226941 | George Albert Fisher|Bristol-Myers Squibb|Stanford University |
Rectal Cancer|Colo-rectal Cancer
|
June 2004 | Phase 1|Phase 2 |
| NCT01647555 | Centre Oscar Lambret |
Epidermoid Head and Neck Cancer
|
November 2006 | |
| NCT02845999 | Centre Hospitalier Universitaire de Besancon|National Cancer Institute, France |
Gastrointestinal Metastatic Cancer
|
November 2009 | Phase 1 |
| NCT01466257 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Head and Neck Cancer
|
November 21, 2011 | |
| NCT00368992 | National Cancer Institute (NCI) |
Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Bronchoalveolar Cell Lung Cancer|Large Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer
|
August 2006 | Phase 2 |
| NCT02252042 | Merck Sharp & Dohme LLC |
Head and Neck Squamous Cell Cancer
|
November 17, 2014 | Phase 3 |
| NCT03774680 | Ahmed A. H. Abdellatif|Al-Azhar University |
Colon Cancer|Colo-rectal Cancer
|
February 1, 2020 | Phase 1 |
| NCT00061815 | Eli Lilly and Company|Bristol-Myers Squibb |
Colorectal Cancer
|
March 2003 | Phase 3 |
| NCT01046266 | Hoffmann-La Roche |
Head and Neck Cancer
|
November 2009 | Phase 1 |
| NCT02928224 | Pfizer|Merck KGaA, Darmstadt, Germany|Pierre Fabre Medicament|Ono Pharmaceutical Co. Ltd |
BRAF V600E-mutant Metastatic Colorectal Cancer
|
October 13, 2016 | Phase 3 |
| NCT02636088 | Gabriella Alexandersson von Döbeln|Karolinska University Hospital |
Esophageal Neoplasm
|
January 2011 | Phase 2 |
| NCT00733889 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Merck Sharp & Dohme LLC|Sanofi |
Esophageal Carcinoma
|
December 2006 | Phase 2 |
| NCT04495621 | Menarini Group |
Metastatic Colorectal Cancer
|
July 20, 2020 | Phase 1|Phase 2 |
| NCT00925015 | Merck Sharp & Dohme LLC |
Colorectal Cancer
|
June 17, 2009 | Phase 1 |
| NCT01184482 | Georgetown University|GlaxoSmithKline |
Colorectal Cancer|Lung Cancer|Head and Neck Cancer
|
June 2010 | Phase 1 |
| NCT01450319 | Merck KGaA, Darmstadt, Germany|Merck, S.L., Spain |
Colorectal Neoplasms
|
December 2011 | Phase 2 |
| NCT01360827 | Merck KGaA, Darmstadt, Germany |
Squamous Cell Carcinoma of the Head and Neck
|
August 2010 | Phase 1 |
| NCT04554836 | TheraOp |
Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum
|
December 29, 2020 | Phase 2 |
| NCT00085501 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lung Cancer
|
July 2004 | Phase 2 |
| NCT00330746 | National Cancer Institute, Naples |
Advanced Non-Small Cell Lung Cancer
|
November 2005 | Phase 2 |
| NCT01004731 | University of Alabama at Birmingham|Eli Lilly and Company |
Stage IV Non-small Cell Lung Cancer
|
June 2001 | Phase 1|Phase 2 |
| NCT00975897 | Medical Research Council|National Cancer Institute (NCI) |
Colorectal Cancer
|
July 2009 | Phase 2|Phase 3 |
| NCT02800486 | Northwell Health |
Glioblastoma|Anaplastic Astrocytoma|Anaplastic Oligoastrocytoma|Glioma|Brain Neoplasm|Brain Cancer|Brain Tumor|Brain Tumor, Recurrent|Brain Neoplasm, Malignant
|
May 2016 | Phase 2 |
| NCT04008030 | Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd |
Metastatic Colorectal Cancer
|
August 5, 2019 | Phase 3 |
| NCT05278351 | Shanghai Zhongshan Hospital |
Colorectal Neoplasms Malignant
|
June 1, 2022 | Phase 2 |
| NCT01068132 | Regione Lombardia|Mario Negri Institute for Pharmacological Research|Istituto Clinico Humanitas|A.O. Ospedale Papa Giovanni XXIII |
Colorectal Cancer
|
April 2009 | Phase 2 |
| NCT02675946 | Curegenix Inc.|Merck Sharp & Dohme LLC |
Solid Tumors|GI Cancer
|
February 2016 | Phase 1 |
| NCT00388427 | University of Pittsburgh|Bristol-Myers Squibb |
Malignant Solid Tumour
|
June 2007 | Phase 1 |
| NCT00956007 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology |
Head and Neck Cancer
|
November 2009 | Phase 3 |
| NCT00499031 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Cervical Squamous Cell Carcinoma|Recurrent Cervical Carcinoma
|
June 2007 | Phase 2 |
Appearance
Liquid
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
References
- [1] Goldstein NI, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995 Nov;1(11):1311-8.
- [2] Gustafsson H, et al. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model. Cell Biochem Biophys. 2017 Jul 29.
- [3] Huang SM, et al. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999 Apr 15;59(8):1935-40.
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.